Descriptor: "MESH: Neoplasm Recurrence, Local" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"MESH: Neoplasm Recurrence, Local"' showing total 114 results

Start Over Descriptor "MESH: Neoplasm Recurrence, Local"

114 results on '"MESH: Neoplasm Recurrence, Local"'

1. Stereotactic radiosurgery for post operative brain metastasic surgical cavities: a single institution experience

Author: Cantaloube, Marie, Boucekine, Mohamed, Balossier, Anne, Muracciole, Xavier, Meyer, Mickael, Delsanti, Christine, Carron, Romain, Beltaifa, Yassine Mohamed, Figarella-Branger, Domnique, Regis, Jean, Padovani, Laetitia, Service de radiothérapie - [Hôpital de la Timone - Hôpital Nord - APHM], Hôpital de la Timone [CHU - APHM] (TIMONE)- Hôpital Nord [CHU - APHM], Genome Instability and Carcinogenesis, Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), APHM, Hôpital de la Timone, Service de Neurochirurgie Fonctionnelle et Stéréotaxique, Méthodes computationnelles pour la prise en charge thérapeutique en oncologie : Optimisation des stratégies par modélisation mécaniste et statistique (COMPO), Inria Sophia Antipolis - Méditerranée (CRISAM), Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Centre de Recherche en Cancérologie de Marseille (CRCM), Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Service d'Anatomo-Cyto-Pathologie et de NeuroPathologie [Hôpital de la Timone - APHM] (ACPNP), and Aix Marseille Université (AMU)- Hôpital de la Timone [CHU - APHM] (TIMONE)
Subjects: Salvage Therapy, MESH: Humans, Brain Neoplasms, Gamma Knife, Brain metastasis, Brain, MESH: Retrospective Studies, [SDV.CAN]Life Sciences [q-bio]/Cancer, Radiosurgery, Resection, MESH: Salvage Therapy, MESH: Brain, Treatment Outcome, Oncology, MESH: Radiosurgery, MESH: Brain Neoplasms, Humans, Radiology, Nuclear Medicine and imaging, Neoplasm Recurrence, Local, MESH: Neoplasm Recurrence, Local, Tumor bed, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Retrospective Studies, MESH: Treatment Outcome
Abstract: Background The standard therapy for brain metastasis was surgery combined with whole brain radiotherapy (WBRT). The latter is however, associated with important neurocognitive toxicity. To reduce this toxicity, postoperative stereotactic radiosurgery (SRS) is a promising technique. We assessed the efficacy and the tolerance to postoperative Gamma Knife radiosurgery (GK) on the tumor bed after resection of brain metastases. Methods Between February 2011 and December 2016, following macroscopic complete surgical resection, 64 patients and 65 surgical cavities were treated by GK in our institution. The indication for adjuvant radiosurgery was a multidisciplinary decision. The main assessment criteria considered in this study were local control, intracranial metastasis-free survival (ICMFS), overall survival and toxicity. Results Median follow-up: 11.1 months. Median time between surgery and radiosurgery: 35 days. Median dose was 20 Gy prescribed to the 50% isodose line, for a median treated volume of 5.6 cc. Four patients (7%) suffered from local recurrence. Local recurrence-free, intracranial recurrence-free and overall survival at 1 year were 97.5%, 57.6% and 62.4% respectively. In total, 23 patients (41%) suffered from intracranial recurrence outside the tumor bed. In univariate analysis: concomitant GK treatment of multiple lesions and the tumor bed was associated with a decrease in ICMFS (HR = 1.16 [1.005–1.34] p = 0.04). In multivariate analysis: a non-lung primary tumor was significantly associated with a decrease in ICMFS (HR = 8.04 [1.82–35.4] p = 0.006). An increase in performance status (PS) and in the initial number of cerebral metastases significantly reduced overall survival (HR = 5.4 [1.11–26.3] p = 0.037, HR = 2.7 [1.004–7.36] p = 0.049, respectively) and One radiation necrosis histologically proven. Conclusion Our study confirmed that postoperative GK after resection of cerebral metastases is an efficient and well-tolerated technique, to treat volumes of all sizes (0.8 to 40 cc). Iterative SRS or salvage WBRT can be performed in cases of intracranial relapse, postponing WBRT with its potential side effects.
Published: 2022
Full Text: View/download PDF

2. Lack of Prognostic Value of CTNNB1 Mutation Profile in Desmoid-Type Fibromatosis

Author: Nicolas Penel, Sylvie Bonvalot, André-Michel Bimbai, Alexandra Meurgey, François Le Loarer, Sébastien Salas, Sophie Piperno-Neumann, Christine Chevreau, Pascaline Boudou-Rouquette, Pascale Dubray-Longeras, Jean-Emmanuel Kurtz, Cécile Guillemet, Emmanuelle Bompas, Antoine Italiano, Axel Le Cesne, Daniel Orbach, Julien Thery, Marie-Cécile Le Deley, Jean-Yves Blay, Olivier Mir, Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université de Lille-UNICANCER, Institut Curie [Paris], Université de Bordeaux (UB), Service d’Oncologie Médicale [Hôpital de la Timone - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Marseille medical genetics - Centre de génétique médicale de Marseille (MMG), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Méthodes computationnelles pour la prise en charge thérapeutique en oncologie : Optimisation des stratégies par modélisation mécaniste et statistique (COMPO), Inria Sophia Antipolis - Méditerranée (CRISAM), Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Département d'Oncologie Médicale [Institut Curie, Paris], Institut Claudius Regaud, Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), UNICANCER, Les Hôpitaux Universitaires de Strasbourg (HUS), Service d'Oncologie Médicale, CRLCC Haute Normandie-Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), Laboratory of Solid Tumors Genetics, Nice University Hospital, Institut de signalisation, biologie du développement et cancer (ISBDC), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), Institut Gustave Roussy (IGR), Département de médecine oncologique [Gustave Roussy], Centre d'Etudes Médiévales de Montpellier (CEMM), Université Paul-Valéry - Montpellier 3 (UPVM), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de biostatistique et d'épidémiologie (SBE), Direction de la recherche clinique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Université Paris Descartes - Faculté de Médecine (UPD5 Médecine), and Université Paris Descartes - Paris 5 (UPD5)
Subjects: Cancer Research, MESH: Humans, Oncology, MESH: beta Catenin, MESH: Fibromatosis, Aggressive, MESH: Adult, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Female, MESH: Cohort Studies, MESH: Neoplasm Recurrence, Local, MESH: Male, MESH: Prognosis, MESH: Prospective Studies
Abstract: Purpose: This prospective nationwide cohort study aimed to investigate desmoid-type fibromatosis (DF) outcomes, focusing on the prognostic value of CTNNB1 mutations. Experimental Design: ALTITUDES (NCT02867033) was a nationwide prospective cohort study of DF diagnosed between January 2016 and December 2020. At diagnosis, CTNNB1 molecular alterations were identified using next-generation sequencing or Sanger sequencing. The primary endpoint was event-free survival (EFS; progression, relapse, or death). We enrolled 628 patients managed by active surveillance, surgical resection, or systemic treatment as first-line therapy. Results: Overall, 516 (82.2%) patients [368 females (71.3%), median age 40.3 years (range, 1–89)] were eligible for analysis. In 435 (84.3%) cases, there was one CTNNB1 molecular alteration: p.T41A, p.S45F, or p.S45P. The first-line management was active surveillance in 352 (68.2%), surgical resection in 120 (23.3%), and systemic treatments in 44 (8.5%) patients. CTNNB1 mutation distribution was similar across the three therapeutic groups. The median follow-up period was 24.7 (range, 0.4–59.7) months. The estimated 3-year EFS rate was 66.2% [95% confidence interval (CI), 60.5%–71.2%]. DF harboring p.S45F was significantly associated with male sex (P = 0.03), non-abdominal wall sites (P = 0.05), pain (P = 0.007), and large tumor size (P = 0.025). CTNNB1 p.S45F mutation was not significantly associated with EFS, either in univariate (HR, 1.06; 95% CI, 0.65–1.73; P = 0.81) or in multivariate analysis (HR, 0.91; 95% CI, 0.55–1.49; P = 0.71). Conclusions: We found that CTNNB1 mutation profile was associated with unfavorable prognostic factors but was not a prognostic factor for EFS. See related commentary by Greene and Van Tine, p. 3911
Published: 2022
Full Text: View/download PDF

3. Acute Pancreatitis as the Initial Presentation of Pancreatic Adenocarcinoma does not Impact Short- and Long-term Outcomes of Curative Intent Surgery: A Study of the French Surgical Association

Author: Matthieu Faron, François Paye, Philippe Bachellier, Yves-Patrice Le Treut, Renato Micelli Lupinacci, Alain Sauvanet, Jean-Robert Delpero, A. Beauchet, Jean-Yves Mabrut, Mustapha Adham, Service de chirurgie générale, digestive et oncologique [CHU Ambroise-Paré], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Ambroise Paré [AP-HP], Institut Gustave Roussy (IGR), Département de chirurgie viscérale [Gustave Roussy], Hôpital de Hautepierre [Strasbourg], Service d’Hépatologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Ambroise Paré [AP-HP], Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), Hôpital Edouard Herriot [CHU - HCL], Department of Surgical Oncology, Université de la Méditerranée - Aix-Marseille 2, Service de chirurgie générale et digestive [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Saint-Antoine [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Subjects: Male, medicine.medical_specialty, recurrence, complications, pancreatic ductal adenocarcinoma, [SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery, Adenocarcinoma, survival, 03 medical and health sciences, pancreatic fistula, Pancreatectomy, 0302 clinical medicine, MESH: Pancreatectomy, medicine, Humans, Retrospective Studies, MESH: Humans, MESH: Middle Aged, MESH: Carcinoma, Pancreatic Ductal, business.industry, MESH: Adenocarcinoma, MESH: Retrospective Studies, Middle Aged, Vascular surgery, medicine.disease, MESH: Male, Acute pancreatitis, 3. Good health, Surgery, Cardiac surgery, Pancreatic Neoplasms, MESH: Pancreatitis, Pancreatitis, Pancreatic fistula, Cardiothoracic surgery, 030220 oncology & carcinogenesis, Acute Disease, MESH: Acute Disease, 030211 gastroenterology & hepatology, MESH: Pancreatic Neoplasms, Neoplasm Recurrence, Local, Complication, business, MESH: Neoplasm Recurrence, Local, Carcinoma, Pancreatic Ductal, Abdominal surgery
Abstract: International audience; BackgroundAcute pancreatitis (AP) can be one of the earliest clinical presentation of pancreatic ductal adenocarcinoma (PDAC). Information about the impact of AP on postoperative outcomes as well as its influences on PDAC survival is scarce. This study aimed to determine whether AP as initial clinical presentation of PDAC impact the short- and long-term outcomes of curative intent pancreatic resection.Patients and methodsFrom 2004 to 2009, 1449 patients with PDAC underwent pancreatic resection in 37 institutions (France, Belgium and Switzerland). We used univariate and multivariate analysis to identify factors associated with severe complications and pancreatic fistula as well as overall and disease-free survivals.ResultsThere were 764 males (52,7%), and the median age was 64 years. A total of 781 patients (53.9%) developed at least one complication, among whom 317 (21.8%) were classified as Clavien–Dindo ≥ 3. A total of 114 (8.5%) patients had AP as the initial clinical manifestation of PDAC. This situation was not associated with any increase in the rates of postoperative fistula (21.2% vs 16.4%, P = 0.19), postoperative complications (57% vs 54.2%, P = 0.56), and 30 day mortality (2.6% vs 3.4%, P = 1). In multivariate analysis, AP did not correlate with postoperative complications or pancreatic fistula. The median length of follow-up was 22.4 months. The median overall survival after surgery was 29.9 months in the AP group and 30.5 months in the control group. Overall recurrence rate and local recurrence rate did not differ between groups.ConclusionAP before PDAC resection did not impact postoperative morbidity and mortality, as well as recurrence rate and survival.
Published: 2021
Full Text: View/download PDF

4. Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial

Author: Marie Véron, Sylvie Chevret, Jean-Jacques Grob, Marie Beylot-Barry, Philippe Saiag, Aude Fléchon, Benoit You, Eve Maubec, Thomas Jouary, Elise Toulemonde, Philippe Jamme, Laëtitia Gambotti, Assia Lamrani-Ghaouti, Alain Dupuy, Céleste Lebbe, Nicole Basset Seguin, Nadine Houede, Marie-Thérèse Leccia, Fanny Le Du, Michel de Pontville, Caroline Gaudy-Marquestre, Bernard Guillot, Clotilde Simon, Aurélien Marabelle, Laurent Mortier, Hôpital Claude Huriez [Lille], CHU Lille, Faculté de Médecine Henri Warembourg - Université de Lille, Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de dermatologie, vénéreologie et cancérologie cutanée [Hôpital de la Timone - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de dermatologie [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], BoRdeaux Institute in onCology (Inserm U1312 - BRIC), Université de Bordeaux (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Ambroise Paré [AP-HP], Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Centre Léon Bérard [Lyon], Hospices Civils de Lyon (HCL), Ciblage thérapeutique en Oncologie (EA3738), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Hôpital Avicenne [AP-HP], Centre hospitalier de Pau, Institut national du cancer [Boulogne] (INCA), UNICANCER, CHU Pontchaillou [Rennes], CIC Saint Louis (CIC-1427), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Centre Hospitalier Universitaire [Grenoble] (CHU), Centre Eugène Marquis (CRLCC), Service de Dermatologie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Hôpital de la Timone [CHU - APHM] (TIMONE), Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Département d’Innovation Thérapeutique et essais précoces [Gustave Roussy] (DITEP), Institut Gustave Roussy (IGR), and Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)
Subjects: Cancer Research, Skin Neoplasms, MESH: Immunotherapy, PD1 blocker, [SDV.CAN]Life Sciences [q-bio]/Cancer, Antineoplastic Agents, MESH: Carcinoma, Basal Cell, Humans, Hedgehog Proteins, Cancer, MESH: Humans, MESH: Skin Neoplasms, Metastatic basal cell carcinoma, MESH: Hedgehog Proteins, Nivolumab, Oncology, Carcinoma, Basal Cell, Basal cell carcinoma, MESH: Antineoplastic Agents, MESH: Nivolumab, Immune checkpoint, Immunotherapy, Neoplasm Recurrence, Local, Locally advanced basal cell carcinoma, MESH: Neoplasm Recurrence, Local, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
Abstract: International audience; Basal cell carcinoma (BCC) is the most common human malignancy. In most cases, BCC has slow progression and can be definitively cured by surgery or radiotherapy. However, in rare cases, it can become locally advanced or, even more rarely, metastatic. The alternative recommended treatments are Sonic Hedgehog pathway inhibitors; however, the response is often short-lived.Methods: This was a phase 2 basket study (NCT03012581) evaluating the efficacy and safety of nivolumab in a cohort of 32 advanced BCC patients, enrolled after failure of Sonic Hedgehog inhibitors, including 29 laBCC (91%) and 3 mBCC (9%).Results: Compared to previously published studies, our population consisted of severe patients with a poor prognosis because they had already received multiple lines of treatment: all patients received previous Sonic Hedgehog inhibitors, 53% of patients already had chemotherapy and 75% radiotherapy. At 12 weeks, we reported 3.1% of complete responses, 18.8% of partial responses, and 43.8% of stable diseases. The best response rate to nivolumab reached 12.5% of complete responses (four patients), 18.8% of partial responses (three patients), and 43.8% of stable diseases (14 patients). Adverse events (AE) were mostly grade 2 or 3, slightly different to the adverse events observed in the treatment of metastatic melanoma (higher rate of diabetes, no thyroid dysfunction).Conclusion: Nivolumab is a relevant therapeutic option for patients with advanced relapsing/refractory BCC.
Published: 2022
Full Text: View/download PDF

5. Small Steatotic HCC: A Radiological Variant Associated With Improved Outcome After Ablation

Author: Eric Assenat, Chloé Guillot, Margaux Hermida, Astrid Herrero, Christophe Cassinotto, Georges-Philippe Pageaux, Fabrizio Panaro, Ancelin Preel, Boris Guiu, Lauranne Piron, José Ursic-Bedoya, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), Institut de Génétique Moléculaire de Montpellier (IGMM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Institut Desbrest de santé publique (IDESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), and Retiveau, Nolwenn
Subjects: Male, Percutaneous, Cirrhosis, [SDV.MHEP.CHI] Life Sciences [q-bio]/Human health and pathology/Surgery, medicine.medical_treatment, Gastroenterology, MESH: Magnetic Resonance Imaging, Liver disease, MESH: Liver Neoplasms, Neoplasm Metastasis, MESH: Carcinoma, Hepatocellular, MESH: Treatment Outcome, MESH: Aged, MESH: Middle Aged, medicine.diagnostic_test, Liver Neoplasms, Hazard ratio, MESH: Follow-Up Studies, Middle Aged, Ablation, Magnetic Resonance Imaging, Treatment Outcome, Hepatocellular carcinoma, Catheter Ablation, Original Article, Female, MESH: Neoplasm Recurrence, Local, medicine.medical_specialty, Carcinoma, Hepatocellular, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery, Disease-Free Survival, [SDV.CAN] Life Sciences [q-bio]/Cancer, Internal medicine, medicine, Humans, Clinical significance, lcsh:RC799-869, Aged, Retrospective Studies, MESH: Humans, MESH: Catheter Ablation, Hepatology, business.industry, MESH: Retrospective Studies, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Magnetic resonance imaging, Original Articles, medicine.disease, MESH: Neoplasm Metastasis, MESH: Male, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, digestive system diseases, MESH: Disease-Free Survival, lcsh:Diseases of the digestive system. Gastroenterology, Neoplasm Recurrence, Local, business, MESH: Female, Follow-Up Studies
Abstract: Percutaneous thermal ablation is a validated treatment option for small hepatocellular carcinoma (HCC). Steatotic HCC can be reliably detected by magnetic resonance imaging. To determine the clinical relevance of this radiological variant, we included 235 patients (cirrhosis in 92.3%, classified Child‐Pugh A in 97%) from a prospective database on percutaneous thermal ablation for 100 ng/mL (P = 0.045), and multifocality (P = 0.015). During the follow‐up (median: 28.3 months), overall mortality (3.8% vs. 23.5%; P = 0.001) and HCC‐specific mortality (0.0% vs. 14.2%; P = 0.002) rates were lower in patients with steatotic HCC. Early (, Small steatotic HCC is reliably detected by MRI and is associated with slightly less advanced liver disease and a less aggressive tumor phenotype. PTA of such radiological HCC variant results in low rate of early recurrence and HCC‐related deaths, longer time‐to‐recurrence, longer recurrence‐free and overall survivals.
Published: 2020
Full Text: View/download PDF

6. Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III

Author: M.J. Reike, M.A. Ingersoll, D.C. Müller, T.C.M. Zuiverloon, T. Strandgaard, A.M. Kamat, S.B. Williams, R. Seiler, T. Todenhöfer, L. Dyrskjøt, R. Nawroth, P. Goebell, B. Schmitz-Dräger, J.P. Sfakianos, J. Meeks, A. Horowitz, P.C. Black, University of British Columbia [Vancouver], Inflammation et immunité des muqueuses - Mucosal Inflammation and Immunity, Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), University of Basel (Unibas), Erasmus University Medical Center [Rotterdam] (Erasmus MC), Aarhus University Hospital, Aarhus University [Aarhus], The University of Texas Medical School at Houston, The University of Texas Medical Branch (UTMB), Technische Universität München = Technical University of Munich (TUM), University Hospital Erlangen = Uniklinikum Erlangen, Icahn School of Medicine at Mount Sinai [New York] (MSSM), and Northwestern University Feinberg School of Medicine
Subjects: MESH: Humans, Bacillus Calmette-Guerin (BCG), MESH: Immunotherapy, Urology, [SDV]Life Sciences [q-bio], Bladder cancer, MESH: Non-Muscle Invasive Bladder Neoplasms, MESH: Adjuvants, Immunologic, MESH: Neoplasm Invasiveness, MESH: Urinary Bladder Neoplasms, MESH: BCG Vaccine, SDG 3 - Good Health and Well-being, Oncology, MESH: Biology, Immunotherapy, MESH: Neoplasm Recurrence, Local, MESH: Administration, Intravesical
Abstract: International audience; Bacillus Calmette-Guerin (BCG) remains the only FDA-approved first-line therapy in patients with high-risk non-muscle invasive bladder cancer. Recurrences, even after adequate BCG therapy, are common and the efficacy of second-line therapies remains modest. Therefore, early identification of patients likely to recur and treatment after recurrence remain critical unmet needs in the clinical care of bladder cancer patients. To address these deficits, a better understanding of the mechanisms of resistance to BCG-therapy is needed. The virtual update of the International Bladder Cancer Network (IBCN) on the biology of response to BCG focused on potential mechanisms and markers of resistance to intravesical BCG therapy. The insights from this meeting will be highlighted and put into context of previously reported mechanisms of resistance to BCG in this review.
Published: 2022
Full Text: View/download PDF

7. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study

Author: Michael Wang, Javier Munoz, Andre Goy, Frederick L. Locke, Caron A. Jacobson, Brian T. Hill, John M. Timmerman, Houston Holmes, Samantha Jaglowski, Ian W. Flinn, Peter A. McSweeney, David B. Miklos, John M. Pagel, Marie José Kersten, Krimo Bouabdallah, Rashmi Khanal, Max S. Topp, Roch Houot, Amer Beitinjaneh, Weimin Peng, Xiang Fang, Rhine R. Shen, Rubina Siddiqi, Ioana Kloos, Patrick M. Reagan, Hematology, Clinical Haematology, AII - Cancer immunology, CCA - Cancer Treatment and Quality of Life, The University of Texas M.D. Anderson Cancer Center [Houston], Microenvironment and B-cells: Immunopathology,Cell Differentiation, and Cancer (MOBIDIC), Université de Rennes (UR)-Etablissement français du sang [Rennes] (EFS Bretagne)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], and University of Rochester Medical Center (URMC)
Subjects: Cancer Research, MESH: Bendamustine Hydrochloride, MESH: Humans, Oncology, MESH: Immunotherapy, Adoptive, MESH: Adult, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Lymphoma, Mantle-Cell, MESH: Follow-Up Studies, MESH: Receptors, Chimeric Antigen, MESH: Neoplasm Recurrence, Local
Abstract: PURPOSE Brexucabtagene autoleucel (KTE-X19) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is approved for the treatment of relapsed/refractory mantle cell lymphoma (MCL). Outcomes after a 3-year follow-up in the pivotal ZUMA-2 study of KTE-X19 in relapsed/refractory MCL are reported, including for subgroups by prior therapy (bendamustine and type of Bruton tyrosine kinase inhibitor [BTKi]) or high-risk characteristics. METHODS Patients with relapsed/refractory MCL (one to five prior therapies, including prior BTKi exposure) received a single infusion of KTE-X19 (2 × 106 CAR T cells/kg). RESULTS After a median follow-up of 35.6 months, the objective response rate among all 68 treated patients was 91% (95% CI, 81.8 to 96.7) with 68% complete responses (95% CI, 55.2 to 78.5); medians for duration of response, progression-free survival, and overall survival were 28.2 months (95% CI, 13.5 to 47.1), 25.8 months (95% CI, 9.6 to 47.6), and 46.6 months (95% CI, 24.9 to not estimable), respectively. Post hoc analyses showed that objective response rates and ongoing response rates were consistent among prespecified subgroups by prior BTKi exposure or high-risk characteristics. In an exploratory analysis, patients with prior bendamustine benefited from KTE-X19, but showed a trend toward attenuated T-cell functionality, with more impact of bendamustine given within 6 versus 12 months of leukapheresis. Late-onset toxicities were infrequent; only 3% of treatment-emergent adverse events of interest in ZUMA-2 occurred during this longer follow-up period. Translational assessments revealed associations with long-term benefits of KTE-X19 including high-peak CAR T-cell expansion in responders and the predictive value of minimal residual disease for relapse. CONCLUSION These data, representing the longest follow-up of CAR T-cell therapy in patients with MCL to date, suggest that KTE-X19 induced durable long-term responses with manageable safety in patients with relapsed/refractory MCL and may also benefit those with high-risk characteristics.
Published: 2022
Full Text: View/download PDF

8. Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model-based population pharmacokinetic analysis

Author: Mourad Hamimed, Pierre Leblond, Aurélie Dumont, Florence Gattacceca, Emmanuelle Tresch-Bruneel, Alicia Probst, Pascal Chastagner, Anne Pagnier, Emilie De Carli, Natacha Entz-Werlé, Jacques Grill, Isabelle Aerts, Didier Frappaz, Anne-Isabelle Bertozzi-Salamon, Caroline Solas, Nicolas André, Joseph Ciccolini, Méthodes computationnelles pour la prise en charge thérapeutique en oncologie : Optimisation des stratégies par modélisation mécaniste et statistique (COMPO), Inria Sophia Antipolis - Méditerranée (CRISAM), Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Simulation and Modeling of Adaptive Response for Therapeutics in Cancer (SMARTc), and Centre de Recherche en Cancérologie de Marseille (CRCM)
Subjects: Pharmacology, Cancer Research, MESH: Humans, MESH: Polymorphism, Single Nucleotide, [SDV]Life Sciences [q-bio], MESH: Models, Biological, MESH: Pharmacogenetics, ABCB1, Vinorelbine, P-glycoprotein, Toxicology, Models, Biological, Polymorphism, Single Nucleotide, Population pharmacokinetic analysis, Oncology, Pediatric drug development, Pharmacogenetics, MESH: Child, Humans, Pharmacology (medical), MESH: Vinorelbine, Neoplasm Recurrence, Local, Child, MESH: Neoplasm Recurrence, Local
Abstract: Better understanding of pharmacokinetics of oral vinorelbine (VNR) in children would help predicting drug exposure and, beyond, clinical outcome. Here, we have characterized the population pharmacokinetics of oral VNR and studied the factors likely to explain the variability observed in VNR exposure among young patients.We collected blood samples from 36 patients (mean age 11.6 years) of the OVIMA multicentric phase II study in children with recurrent/progressive low-grade glioma. Patients received 60 mg/mA three-compartment model, with a delayed double zero-order absorption and a first-order elimination, best described VNR pharmacokinetics in children. Typical population estimates for the apparent central volume of distribution (VBeyond canonical BSA and leukocytes, ABCB1-rs2032582 polymorphism showed a meaningful impact on VNR systemic exposure. Simulations showed that the identified covariates could have an impact on both efficacy and toxicity outcomes. Thus, a personalized dosing strategy, using those covariates, could help to optimize the efficacy/toxicity balance of VNR in children.
Published: 2022
Full Text: View/download PDF

9. Impact of severe obesity in the management of patients with high-risk endometrial cancer: A FRANCOGYN study

Author: Ombline Simon, Ludivine Dion, Krystel Nyangoh Timoh, Pierre François Dupré, Henri Azaïs, Sofiane Bendifallah, Cyril Touboul, Yohan Dabi, Olivier Graesslin, Emilie Raimond, Hélène Costaz, Yohan Kerbage, Cyrille Huchon, Camille Mimoun, Martin Koskas, Cherif Akladios, Lise Lecointre, Geoffroy Canlorbe, Pauline Chauvet, Lobna Ouldamer, Jean Levêque, Vincent Lavoué, CHU Pontchaillou [Rennes], Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Universitaire de Reims (CHU Reims), Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER, CHU Lille, Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), AP-HP - Hôpital Bichat - Claude Bernard [Paris], CHU Strasbourg, CHU Pitié-Salpêtrière [AP-HP], CHU Clermont-Ferrand, CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Oncogenesis, Stress, Signaling (OSS), Université de Rennes (UR)-CRLCC Eugène Marquis (CRLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Jonchère, Laurent
Subjects: MESH: Humans, Clinical management, MESH: Lymph Node Excision, [SDV]Life Sciences [q-bio], Obstetrics and Gynecology, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics, MESH: Obesity, Morbid, Endometrial Neoplasms, Obesity, Morbid, [SDV] Life Sciences [q-bio], [SDV.MHEP.GEO] Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics, [SDV.CAN] Life Sciences [q-bio]/Cancer, Endometrial cancer, Reproductive Medicine, Humans, Lymph Node Excision, MESH: Obesity, Female, Surgery, Obesity, MESH: Endometrial Neoplasms, Neoplasm Recurrence, Local, MESH: Female, MESH: Neoplasm Recurrence, Local
Abstract: International audience; Objective: To assess the surgical management and survival of severely obese patients with high-risk endometrial cancer.Materials and methods: Data from 269 patients with high-risk endometrial cancer who were treated between 2001 and 2018 were collected from a multicenter database (11 centers). We classified the patients according to their BMI and compared outcomes in two groups: a normal weight group of women with a BMI < 25 kg/m2, and a severe obesity group of women with a BMI ≥ 35 kg/m2. The groups were compared for epidemiologic, pathologic, management, relapse-free survival (RFS) and overall survival (OS) elements.Results: Patients in the severe obesity group were younger (64 years vs. 68 years, p < 0.05) and had more comorbidities (hypertension, diabetes). They also had more locally advanced tumors and pelvic lymph node involvement (47% vs 24%, p < 0.05). The severely obese patients were less likely to undergo recommended surgical staging, with fewer lumbar aortic dissections than women of normal weight (23% vs 36%, p < 0.05) and fewer pelvic sentinel lymph node biopsies (26.5% vs 12.1%, p < 0.05). No difference in RFS or OS were observed between the two groups.Conclusion: Patients with severe obesity and high-risk endometrial cancer have more locally advanced tumors, and are less likely to be managed according to surgical recommendations. However, RFS and OS do not seem to be affected.
Published: 2022
Full Text: View/download PDF

10. HCV Eradication in Primary or Secondary Prevention Optimizes Hepatocellular Carcinoma Curative Management

Author: Nahon, Pierre, Layese, Richard, Cagnot, Carole, Asselah, Tarik, Guyader, Dominique, Pol, Stanislas, Pageaux, Georges-Philippe, de Lédinghen, Victor, Ouzan, Denis, Zoulim, Fabien, Audureau, Etienne, Cirvir Group, Anrs Co12, Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris 13 (UP13), Génomique fonctionnelle des tumeurs solides = Functional Genomics of Solid Tumors [CRC] (FunGeST), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Clinical Epidemiology and Ageing : Geriatrie Soins Primaires et Santé Publique (CEpiA), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS), Hôpital Beaujon [AP-HP], Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Pontchaillou [Rennes], Hôpital Cochin [AP-HP], Physiopathologie du système immunitaire (Inserm U1223), Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Descartes - Paris 5 (UPD5), Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Institut Arnault Tzanck, Université de Lyon, Hospices Civils de Lyon (HCL), This study was sponsored by the ANRS (France REcherche Nord & sud Sida-hiv Hépatites: FRENSH). This work was also supported, in part, by a grant from AbbVie., ANRS CO12 CirVir group: Pierre Nahon, Tarik Asselah, Dominique Guyader, Stanislas Pol, Hélène Fontaine, Dominique Larrey, Victor De Lédinghen, Denis Ouzan, Fabien Zoulim, Dominique Roulot, Albert Tran, Jean-Pierre Bronowicki, Jean-Pierre Zarski, Vincent Leroy, Ghassan Riachi, Paul Calès, Jean-Marie Péron, Laurent Alric, Marc Bourlière, Philippe Mathurin, Sebastien Dharancy, Jean-Frédéric Blanc, Armand Abergel, Lawrence Serfaty, Ariane Mallat, Jean-Didier Grangé, Pierre Attali, Yannick Bacq, Claire Wartelle, Thông Dao, Dominique Thabut, Christophe Pilette, Christine Silvain, Christos Christidis, Eric Nguyen-Khac, Brigitte Bernard-Chabert, Sophie Hillaire, Vincent Di Martino., École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité)-École Pratique des Hautes Études (EPHE), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Liver Cirrhosis, Male, 0301 basic medicine, Cancer Research, Multivariate analysis, Cirrhosis, Sustained Virologic Response, [SDV]Life Sciences [q-bio], MESH: Sustained Virologic Response, Hepacivirus, Gastroenterology, 0302 clinical medicine, MESH: Liver Neoplasms, Secondary Prevention, MESH: Hepacivirus, Prospective Studies, MESH: Incidence, MESH: Carcinoma, Hepatocellular, Secondary prevention, MESH: Aged, MESH: Middle Aged, MESH: Secondary Prevention, Incidence, Liver Neoplasms, MESH: Follow-Up Studies, Middle Aged, MESH: Hepatitis C, Chronic, Oncology, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, Cohort, Female, MESH: Liver Cirrhosis, MESH: Neoplasm Recurrence, Local, MESH: Antiviral Agents, medicine.medical_specialty, Carcinoma, Hepatocellular, Antiviral Agents, Disease-Free Survival, 03 medical and health sciences, Internal medicine, medicine, Humans, Aged, MESH: Humans, business.industry, Hepatitis C, Chronic, medicine.disease, BCLC Stage, digestive system diseases, MESH: Male, MESH: Prospective Studies, Regimen, 030104 developmental biology, MESH: Disease-Free Survival, Liver function, Neoplasm Recurrence, Local, business, MESH: Female, Follow-Up Studies
Abstract: To assess the impact of HCV eradication on the outcomes of cirrhotic patients treated curatively for incidental hepatocellular carcinoma (HCC) detected during surveillance program. Data were collected on 1,323 French patients with compensated biopsy-proven HCV cirrhosis recruited in 35 centers (ANRS CO12 CirVir cohort). Sustained virologic responses (SVR) and the occurrence of HCC were recorded prospectively. During a median follow-up of 68.3 months, 218 patients developed HCC, 126 of whom underwent a curative procedure as first-line therapy (ablation = 95, resection = 31). The HCC BCLC stage was 0/A in 97.5% of patients; 74 (58.7%) never achieved SVR. During a median follow-up of 26.0 months after HCC treatment, 59 (46.8%) experienced HCC recurrence. SVR was not associated with a recurrence, whether considering final SVR status [HR = 0.77; 95% confidence interval (95% CI), 0.43–1.39; P = 0.39] or its time to achievement (prior to/after HCC occurrence; global P = 0.28). During the same timeframe, 46 patients with HCC (36.5%) died (liver failure: 41.9%, HCC progression: 37.2%, extrahepatic causes: 20.9%). Under multivariate analysis, SVR was associated with improved survival [HR = 0.21; 95% CI, 0.08–0.52; P = 0.001]. Survival benefit was explained by a lower incidence of liver decompensation and higher rates of sequential HCC re-treatment. Direct antiviral intake was not associated with a higher risk of HCC recurrence, but with improved survival (HR = 0.23; 95% CI, 0.06–0.83; P = 0.024). HCV eradication in primary or secondary prevention optimizes HCC management through preservation of liver function and improves survival, whatever the regimen. Prevention Relevance: Liver failure is a competing risk of death in patients with HCC eligible for curative procedures. HCV eradication does not decrease risk of HCC recurrence in the first two years, but enables sequential curative HCC treatments through preservation of liver function. Direct-acting antiviral agent intake is not associated with HCC recurrence and improves survival.
Published: 2021
Full Text: View/download PDF

11. Efficacy and safety of treatments in cutaneous polyarteritis nodosa: A French observational retrospective study

Author: Selim Aractingi, Florence Cordoliani, François Chasset, L. Frumholtz, Jean-David Bouaziz, Romain Paule, Alexis Régent, Nicolas Dupin, Benjamin Terrier, Thomas Bettuzzi, Marie Jachiet, Loïc Guillevin, Luc Mouthon, Emilie Sbidian, Service de dermatologie [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service de Dermatologie [AP-HP Hôpital Saint-Louis], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), EPI-PHARE (EPI-PHARE), Caisse nationale d'assurance maladie des travailleurs salariés [CNAMTS]-Agence nationale de sécurité du médicament et des produits de santé [Saint-Denis] (ANSM), Epidemiology in Dermatology and Evaluation in Therapeutics (EpiDermE), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre d'Investigation Clinique Henri Mondor (CIC Henri Mondor), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service de dermatologie [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Hôpital Cochin [AP-HP], Université Paris Cité (UPCité), Service de dermatologie et allergologie [CHU Tenon], CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Réseaux & Optimisation Combinatoire et Stochastique (ROCS), Laboratoire Interdisciplinaire des Sciences du Numérique (LISN), CentraleSupélec-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-CentraleSupélec-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Science des Données (SDD), CentraleSupélec-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-CentraleSupélec-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Service de médecine interne et centre de référence des maladies rares [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Université Paris Cité (UPC), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut National de Recherche en Informatique et en Automatique (Inria)-CentraleSupélec-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche en Informatique et en Automatique (Inria)-CentraleSupélec-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Science des Données (SDD), and Institut National de Recherche en Informatique et en Automatique (Inria)-CentraleSupélec-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche en Informatique et en Automatique (Inria)-CentraleSupélec-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)
Subjects: medicine.medical_specialty, Cutaneous Polyarteritis Nodosa, Azathioprine, Dermatology, Dapsone, methotrexate, vasculitis, MESH: Polyarteritis Nodosa, Interquartile range, Internal medicine, Medicine, Humans, Adverse effect, Glucocorticoids, MESH: Azathioprine, Retrospective Studies, MESH: Humans, treatment, business.industry, cutaneous polyarteritis nodosa, Retrospective cohort study, MESH: Retrospective Studies, medicine.disease, humanities, Discontinuation, Polyarteritis Nodosa, body regions, MESH: Colchicine, Neoplasm Recurrence, Local, business, Vasculitis, MESH: Glucocorticoids, Colchicine, MESH: Neoplasm Recurrence, Local, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology, medicine.drug
Abstract: Background Cutaneous polyarteritis nodosa is a form of medium-sized vessel vasculitis. Despite a disabling and prolonged course, data on treatment efficacy and safety remain scarce. Objectives We aimed to describe treatment efficacy and safety in patients with cutaneous polyarteritis nodosa. Methods This multicenter retrospective, observational study, recorded clinical and biologic data together with treatments received. The primary outcome was the rate of complete response at month 3. Secondary outcomes assessed drug survival and safety. Results We included 68 patients who received a median of 2 therapeutic lines (interquartile range, 1-3). Overall, complete response was achieved in 13 of 42 (31%) patients with colchicine, 4 of 17 (23%) with dapsone, 11 of 25 (44%) with glucocorticoids (GCs) alone, 1 of 9 (11%) with nonsteroidal anti-inflammatory drugs, 11 of 13 (84%) with GCs+azathioprine, and 7 of 15 (47%) with GCs+methotrexate. GCs+azathioprine had the best drug survival (median duration, 29.5 months; interquartile range, 19.5-36.0). Response at month 3 was decreased with peripheral neurologic involvement (odds ratio, 0.19; 95% confidence interval, 0.03-0.81; P = .04). Overall, the rate of treatment-related adverse events was 18%, which led to the discontinuation of treatment in 7% of patients. Limitation Retrospective study. Conclusion Colchicine seems to confer good benefit-risk balance in cutaneous polyarteritis nodosa without peripheral sensory neuropathy. GCs+azathioprine seem the best treatment in the event of relapse.
Published: 2021
Full Text: View/download PDF

12. Guidelines of the French Society of Otorhinolaryngology–Head and Neck Surgery (SFORL), part II: Management of recurrent pleomorphic adenoma of the parotid gland

Author: C.-A. Righini, C. Cartier, P. Mogultay, Renaud Garrel, Nicolas Fakhry, Emmanuelle Uro-Coste, Dominique Chevalier, A. Varoquaux, M. Courtade-Saidi, Sébastien Vergez, T. Kennel, Olivier Malard, S. Tronche, Juliette Thariat, Laboratoire de physique corpusculaire de Caen (LPCC), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-École Nationale Supérieure d'Ingénieurs de Caen (ENSICAEN), Normandie Université (NU)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Hôtel-Dieu de Nantes, Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Lille, Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Société française d'ORL et chirurgie cervico-faciale (SFORL), Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Centre Hospitalier Universitaire [Grenoble] (CHU), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), and Michel-Avella, Amandine
Subjects: medicine.medical_specialty, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Adenoma, Pleomorphic, Salivary glands, Complete resection, complex mixtures, MESH: Salivary Gland Neoplasms, Pleomorphic adenoma, Otolaryngology, 03 medical and health sciences, 0302 clinical medicine, Recurrence, Humans, Parotid Gland, Medicine, MESH: Parotid Gland, MESH: Parotid Neoplasms, 030223 otorhinolaryngology, Parotid, Subclinical infection, [PHYS]Physics [physics], MESH: Humans, business.industry, General surgery, Evidence-based medicine, MESH: Adenoma, Pleomorphic, Salivary Gland Neoplasms, medicine.disease, MESH: Otolaryngology, Parotid Neoplasms, 3. Good health, Parotid gland, Radiation therapy, [SDV] Life Sciences [q-bio], medicine.anatomical_structure, Otorhinolaryngology, 030220 oncology & carcinogenesis, Head and neck surgery, Surgery, Neoplasm Recurrence, Local, business, MESH: Neoplasm Recurrence, Local
Abstract: International audience; Introduction: The authors present the guidelines of the French Society of Otorhinolaryngology-Head and Neck Surgery (SFORL) for the management of recurrent pleomorphic adenoma (RPA) of the parotid gland.Method: A review of the literature was performed by a multidisciplinary task force. Guidelines were drafted, based on the articles retrieved and the work group members' individual experience. There were then read and re-edited by an independent reading group. The proposed recommendations were graded A, B or C on decreasing levels of evidence.Results: Complete resection under neuromonitoring is recommended in case of RPA. The risks of progression and malignant transformation, which are higher the younger the patient, have to be taken into consideration. The risk of functional sequelae must be explained to the patient. MRI is recommended ahead of any surgery for parotid RPA, to determine extension and detect subclinical lesions. Radiotherapy should be considered in case of multi-recurrent pleomorphic adenoma after macroscopically complete revision surgery at high risk of new recurrence (microscopic residual disease), in case of RPA after incomplete resection, and in non-operable RPA.
Published: 2021
Full Text: View/download PDF

13. BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS

Author: Cohen, Mikael, Mondot, Lydiane, Bucciarelli, Florence, Pignolet, Béatrice, Laplaud, David-Axel, Wiertlewski, Sandrine, Brochet, Bruno, Ruet, Aurélie, Defer, Gilles, Derache, Nathalie, Vermersch, Patrick, Zephir, Hélène, Debouverie, Marc, Mathey, Guillaume, Berger, Eric, Cappé, Chrystelle, Labauge, Pierre, Carra, Clarisse, de Seze, Jérôme, Bigaut, Kevin, Brassat, David, Lebrun-Frenay, Christine, Service de Neurologie [CHU Nice], Hôpital Pasteur [Nice] (CHU)-Centre Hospitalier Universitaire de Nice (CHU Nice), Hôpital Pasteur [Nice] (CHU), Pôle Neurosciences [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), Service de neurologie [Nantes], Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Hôpital Guillaume-et-René-Laennec [Saint-Herblain], Service de neurologie [Bordeaux], CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Service de Neurologie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Lille Neurosciences & Cognition - U 1172 (LilNCog), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre d'investigation clinique - Epidémiologie clinique [Nancy] (CIC-EC), Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Service de Neurologie [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre d'Investigation Clinique de Besançon (Inserm CIC 1431), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), CIC Strasbourg (Centre d’Investigation Clinique Plurithématique (CIC - P) ), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Nouvel Hôpital Civil de Strasbourg-Hôpital de Hautepierre [Strasbourg], Service de Neurologie [Strasbourg], and CHU Strasbourg-Hopital Civil
Subjects: MESH: Humans, [SDV]Life Sciences [q-bio], MESH: Multiple Sclerosis, MESH: Natalizumab / therapeutic use, MESH: Prospective Studies, Multiple sclerosis, MESH: Fingolimod Hydrochloride* / therapeutic use, natalizumab, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, therapeutics, magnetic resonance imaging, [SDV.IMM]Life Sciences [q-bio]/Immunology, fingolimod, MESH: Neoplasm Recurrence, Local
Abstract: International audience; Background: There are few head-to-head studies to compare highly active treatments in multiple sclerosis (MS) Objective: The aim of this study was to compare the effectiveness between natalizumab (NTZ) and fingolimod (FTY) in active relapsing–remitting MS Method: Best Escalation STrategy in Multiple Sclerosis (BEST-MS) is a multicentric, prospective study with a 12-month follow-up including patients with active MS. Treatment choice was at the discretion of physician. Clinical and magnetic resonance imaging (MRI) data were collected at baseline and at 12 months. The primary outcome was the proportion of patients reaching no evidence of disease activity (NEDA) at 12 months. Secondary outcomes included annualized relapse rate and MRI activity. Results: A total of 223 patients were included (NTZ: 109 and FTY: 114). Treatment groups were well balanced at baseline. Proportion of NEDA patients was 47.8% in NTZ group versus 30.4% in FTY group ( p = 0.015). This superiority was driven by annualized relapse rate and MRI activity. In the multivariate analysis, treatment group was the only factor associated with NEDA at 12 months with a lower probability in FTY group (odds ratio (OR) = 0.49, p = 0.029). Conclusion: BEST-MS is a prospective study that compared head-to-head the effectiveness of NTZ and FTY in active relapsing–remitting MS. Our results suggest a superiority of NTZ over FTY.
Published: 2020
Full Text: View/download PDF

14. The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patients

Author: Cecile Artaud, Marie-Paule Sablin, Jacques Medioni, Pierre Rosenbaum, Sylvie Bay, Olivier Tredan, Christelle Ganneau, Suzette Delaloge, Delphine Loirat, Mario Campone, François Pein, Claude Leclerc, Andrea Varga, Carole Gourmelon, Régulation Immunitaire et Vaccinologie, Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur [Paris], Centre de Recherche Translationnelle - Center for Translational Science (CRT), Institut Pasteur [Paris], Chimie des Biomolécules - Chemistry of Biomolecules, Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris], Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER, Institut Gustave Roussy (IGR), Pathologie mammaire, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Institut Curie [Paris], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Centre Léon Bérard [Lyon], Département d’Innovation Thérapeutique et essais précoces [Gustave Roussy] (DITEP), The work was funded by the donors of the MAG-Tn3 program. GlaxoSmithKline Biological SA provided AS15 and preparing the final formulation of the MAG/AS15 vaccine., Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut Pasteur [Paris] (IP), and Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Cancer Research, Antibodies, Neoplasm, Tn antigen, MESH: Adjuvants, Immunologic, Epitope, MESH: Cancer Vaccines, Jurkat Cells, 0302 clinical medicine, Immunogenicity, Vaccine, Breast cancer, Cancer vaccine, MESH: Jurkat Cells, Immunology and Allergy, Medicine, MESH: Animals, MESH: Treatment Outcome, MESH: Aged, education.field_of_study, Vaccines, Synthetic, MESH: Middle Aged, biology, MESH: Antigens, Tumor-Associated, Carbohydrate, Vaccination, Glycopeptides, MESH: Immunogenicity, Vaccine, Middle Aged, QS21, MESH: Injections, Intramuscular, Glycopeptide, 3. Good health, Treatment Outcome, Oncology, Female, Antibody, MESH: Neoplasm Recurrence, Local, Adult, MESH: Vaccines, Synthetic, Immunology, Population, Breast Neoplasms, Cancer Vaccines, Injections, Intramuscular, Antibodies, 03 medical and health sciences, Immune system, Adjuvants, Immunologic, Animals, Humans, Antigens, Tumor-Associated, Carbohydrate, education, Aged, MESH: Glycopeptides, MESH: Humans, business.industry, MESH: Adult, MESH: Vaccination, [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy, MESH: Antibodies, Neoplasm, biology.protein, Neoplasm Recurrence, Local, business, MESH: Female, MESH: Breast Neoplasms, 030215 immunology
Abstract: International audience; Cancer is one of the main causes of mortality worldwide and a major public health concern. Among various strategies, therapeutic vaccines have been developed to stimulate anti-tumoral immune responses. However, in spite of extensive studies, this approach suffers from a lack of efficacy. Recently, we designed the MAG-Tn3 vaccine, aiming to induce antibody responses against Tn, a tumor-associated carbohydrate antigen. The Tn antigen is of interest because it is expressed by several adenocarcinomas, but not normal cells. The fully synthetic glycopeptide vaccine MAG-Tn3 is composed of four arms built on three adjacent Tn moieties associated with the tetanus toxin-derived peptide TT830-844 CD4+ T-cell epitope. This promiscuous CD4+ T-cell epitope can bind to a wide range of HLA-DRB molecules and is thus expected to activate CD4+ T-cell responses in a large part of the human population. The MAG-Tn3 vaccine was formulated with the GSK-proprietary immunostimulant AS15, composed of CpG7909, MPL, and QS21, which has been shown to stimulate both innate and humoral responses, in addition to being well tolerated. Here, seven patients with localized breast cancer with a high-risk of relapse were immunized with the MAG-Tn3 vaccine formulated with AS15. The first results of phase I clinical trial demonstrated that all vaccinated patients developed high levels of Tn-specific antibodies. Moreover, these antibodies specifically recognized Tn-expressing human tumor cells and killed them through a complement-dependent cytotoxicity mechanism. Overall, this study establishes, for the first time, the capacity of a fully synthetic glycopeptide cancer vaccine to induce specific immune responses in humans.
Published: 2020
Full Text: View/download PDF

15. Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial

Author: Anne Dubois, Jean-Jacques Tuech, Philippe Rouanet, M. Bertrand, Anne Rullier, Marc Pocard, Quentin Denost, Véronique Vendrely, Bertrand Trilling, Mehrdad Jafari, Alain Valverde, G. Portier, Cécile de Chaisemartin, Nora Frulio, Julien Asselineau, Eric Frison, Denis Smith, Eric Rullier, Bernard Meunier, Michel Rivoire, Igor Sieleznieff, Frédéric Marchal, Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], CIC Bordeaux, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), UNICANCER - Institut régional du Cancer Montpellier Val d'Aurelle (ICM), CRLCC Val d'Aurelle - Paul Lamarque, Hôpital Charles Nicolle [Rouen], Groupe Hospitalier Diaconesses Croix Saint-Simon, Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre Léon Bérard [Lyon], Hôpital Michallon, Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université Lille Nord de France (COMUE)-UNICANCER, Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], CHU Pontchaillou [Rennes], Hôpital de la Timone [CHU - APHM] (TIMONE), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), UNICANCER, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Pellegrin, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Salvy-Córdoba, Nathalie, Université de Lille-UNICANCER, and Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)
Subjects: medicine.medical_specialty, [SDV.MHEP.CHI] Life Sciences [q-bio]/Human health and pathology/Surgery, MESH: Survival Rate, MESH: Chemoradiotherapy, Adjuvant, Colorectal cancer, medicine.medical_treatment, MESH: Neoadjuvant Therapy, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery, MESH: Intention to Treat Analysis, MESH: Proportional Hazards Models, 03 medical and health sciences, 0302 clinical medicine, MESH: Aged, 80 and over, [SDV.CAN] Life Sciences [q-bio]/Cancer, medicine, Prospective cohort study, Survival rate, Neoadjuvant therapy, MESH: Kaplan-Meier Estimate, MESH: Aged, Intention-to-treat analysis, MESH: Middle Aged, MESH: Humans, Hepatology, MESH: Organ Sparing Treatments, business.industry, MESH: Proctectomy, Hazard ratio, Gastroenterology, MESH: Rectal Neoplasms, MESH: Adult, MESH: Neoplasm Staging, medicine.disease, Total mesorectal excision, MESH: Neoplasm Metastasis, MESH: Prospective Studies, MESH: Male, 3. Good health, Surgery, 030220 oncology & carcinogenesis, MESH: Disease-Free Survival, 030211 gastroenterology & hepatology, business, MESH: Neoplasm Recurrence, Local, MESH: Female, Chemoradiotherapy
Abstract: Summary Background GRECCAR 2 was the first multicentre, randomised trial to compare local excision with total mesorectal excision in downstaged low rectal cancer. Encouraging oncological results were noted at 3 years' follow-up but needed to be corroborated with longer follow-up. In this study, we aimed to report the 5-year oncological outcomes, including local recurrence, metastatic disease, and survival. Methods Patients age 18 years and older with T2T3 low rectal cancer, of maximum size 4 cm, who were clinically good responders after chemoradiotherapy (residual tumour ≤2 cm) were randomly assigned before surgery to either local excision or total mesorectal excision. Randomisation was centralised and not stratified and used permuted blocks of size eight. In the local excision group, a completion total mesorectal excision was performed if pathological tumour stage was ypT2–3. The primary objective of this study was to assess the 5-year oncological outcomes of local recurrence, metastatic disease, disease-free survival, overall survival, and cancer-specific mortality, which were the secondary endpoints of GRECCAR 2. We used Kaplan-Meier estimates and Cox modelling to estimate and compare recurrence and survival in modified intention-to-treat and as-treated populations. This trial was registered with ClinicalTrials.gov , number NCT00427375 . Findings Between March 1, 2007, and Sept 24, 2012, 148 patients who were good clinical responders were randomly assigned to treatment, three patients were excluded after randomisation (because they had metastatic disease, tumour >8 cm from anal verge, or withdrew consent), leaving 145 for analysis: 74 in the local excision group and 71 in the total mesorectal excision group. Median follow-up was 60 months (IQR 58–60) in the local excision group and 60 months (57–60) in the total mesorectal excision group. 23 patients died and five were lost to follow-up. In the local excision group, 26 had a completion total mesorectal excision for ypT2–3 tumour. In the modified intention-to-treat analysis, there was no difference between the local excision and total mesorectal excision groups in 5-year local recurrence (7% [95% CI 3–16] vs 7% [3–16]; adjusted hazard ratio [HR] 0·71 [95% CI 0·19–2·58]; p=0·60), metastatic disease (18% [CI 11–30] vs 19% [11–31]; 0·86 [0·36–2·06]; p=0·73), overall survival (84% [73–91] vs 82% [71–90]; 0·92 [0·38–2·22]; p=0·85), disease-free survival (70% [58–79] vs 72% [60–82]; 0·87 [0·44–1·72]; p=0·68), or cancer-specific mortality (7% [3–17] vs 10% [5–20]; 0·65 [0·17–2·49]; p=0·53). Interpretation The 5-year results of this multicentre randomised trial corroborate the 3-year results, providing no evidence of difference in oncological outcomes between local excision and total mesorectal excision. Local excision can be proposed in selected patients having a small T2T3 low rectal cancer with a good clinical response after chemoradiotherapy. Funding National Cancer Institute of France.
Published: 2020
Full Text: View/download PDF

16. The management of perineal hernia following abdomino-perineal excision for cancer

Author: M Luong, Najim Chafai, Thibault Voron, Ben Creavin, K Bertrand, Emmanuel Tiret, Yann Parc, Jérémie H. Lefevre, Clotilde Debove, Service de chirurgie générale et digestive [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Sorbonne Université - Faculté de Médecine (SU FM), and Sorbonne Université (SU)
Subjects: Male, MESH: Carcinoma, Hernia, Colorectal cancer, [SDV]Life Sciences [q-bio], 030230 surgery, MESH: Surgical Mesh, Perineum, Surgical Flaps, 0302 clinical medicine, MESH: Aged, 80 and over, Recurrence, Abdomen, Rectal cancer, Perineal hernia, Aged, 80 and over, MESH: Aged, Proctectomy, MESH: Middle Aged, Middle Aged, 3. Good health, 030220 oncology & carcinogenesis, Cohort, Female, MESH: Neoplasm Recurrence, Local, Abdomino-perineal resection, Adult, medicine.medical_specialty, MESH: Abdomen, Resection, 03 medical and health sciences, medicine, MESH: Herniorrhaphy, Humans, MESH: Perineum, Herniorrhaphy, Aged, Retrospective Studies, MESH: Humans, Rectal Neoplasms, business.industry, MESH: Proctectomy, Carcinoma, Cancer, MESH: Rectal Neoplasms, MESH: Adult, MESH: Retrospective Studies, Surgical Mesh, MESH: Surgical Flaps, medicine.disease, MESH: Hernia, Combined approach, MESH: Male, Surgery, MESH: Recurrence, Neoplasm Recurrence, Local, business, Complication, MESH: Female, Abdominal surgery
Abstract: International audience; Purpose: Perineal hernia (PH) is a tardive complication following abdomino-perineal resection (APR). Many repair methods are described and evidences are lacking. The aim of this study was to report PH management, analyze surgery outcomes and review the available literature.Methods: We retrospectively included all consecutive PH repair after APR performed between 2001 and 2017. We recorded data on APR surgery, PH symptoms and repair, and follow-up (recurrence and morbidity). Literature review included published articles on PubMed between 1960 and 2017.Results: 24 PH repairs were included. The approach was perineal N = 16, abdominal N = 5 and combined N = 3. A biological mesh was used for 17, a synthetic for 5 and a flap for 2 patients. The median follow-up was 25 months. Overall morbidity was 37.5% (N = 9): 37.5% for the perineal, 20% for the abdominal, and 66.7% for the combined approach. Complications occurred in 35.3% of biological and 20% of synthetic mesh repairs. Recurrence rate was 41.7%, similar for biological (n = 8, 47.1%) and synthetic meshs (n = 2; 40%). No recurrence occurred in the flap group. Depending of the approach, we found 50% for perineal (n = 8) and 40% of the abdominal cohort (N = 2). Among twelve studies, recurrence rates ranged from 0 to 66.7%. Abdominal or laparoscopic approach with synthetic mesh was associated with less recurrences (0 and 12.5% respectively) and complications (37.5% and 9.5%).Conclusions: Recurrences following PH repair are high irrespective of the repair technique. More studies are necessary to identify PH risk factors and decide the appropriate perineal reconstruction.
Published: 2020
Full Text: View/download PDF

17. The Oncologic Impact of Pancreatic Fistula After Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma of the Body and the Tail: A Multicenter Retrospective Cohort Analysis

Author: Giulio Belfiori, Andrea Casadei Gardini, Stefano Crippa, Ugo Boggi, Vito De Blasi, Francesca Menonna, Fabrizio Panaro, Valentina Sega, Mircea Chirica, Piera Leon, Giusy Giannandrea, Francis Navarro, Abdul Rahman Al Sadairi, Patrick Pessaux, Massimo Falconi, Tullio Piardi, F Ravazzoni, Laurent Sulpice, Fabio Giannone, Leon, P., Giannone, F., Belfiori, G., Falconi, M., Crippa, S., Boggi, U., Menonna, F., Al Sadairi, A. R., Piardi, T., Sulpice, L., Gardini, A., Sega, V., Chirica, M., Ravazzoni, F., Giannandrea, G., Pessaux, P., de Blasi, V., Navarro, F., Panaro, F., Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), IRCCS Ospedale San Raffaele [Milan, Italy], Universita Vita Salute San Raffaele = Vita-Salute San Raffaele University [Milan, Italie] (UniSR), Cisanello Hospital, Centre Hospitalier Universitaire de Reims (CHU Reims), CHU Pontchaillou [Rennes], Ospedale G.B.Morgagni-L. Pierantoni, Partenaires INRAE, Fondazione Poliambulanza, CHU Grenoble, Ospedale SS Antonio e Biagio e Cesare Arrigo, Bari University Hospital, L'Institut hospitalo-universitaire de Strasbourg (IHU Strasbourg), Institut National de Recherche en Informatique et en Automatique (Inria)-l'Institut de Recherche contre les Cancers de l'Appareil Digestif (IRCAD)-Les Hôpitaux Universitaires de Strasbourg (HUS)-La Fédération des Crédits Mutuels Centre Est (FCMCE)-L'Association pour la Recherche contre le Cancer (ARC)-La société Karl STORZ, CHU Luxembourg, Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), and Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)
Subjects: Male, Disease, 030230 surgery, Gastroenterology, Cohort Studies, 0302 clinical medicine, MESH: Aged, 80 and over, Postoperative Complications, Surgical oncology, MESH: Postoperative Complications, MESH: Pancreatectomy, 10. No inequality, MESH: Cohort Studies, MESH: Aged, Aged, 80 and over, MESH: Middle Aged, Incidence (epidemiology), Middle Aged, 3. Good health, medicine.anatomical_structure, Oncology, Pancreatic fistula, 030220 oncology & carcinogenesis, Female, MESH: Pancreatic Neoplasms, Distal pancreatectomy, Pancreas, MESH: Neoplasm Recurrence, Local, Adult, medicine.medical_specialty, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery, 03 medical and health sciences, Pancreatic Fistula, Pancreatectomy, MESH: Pancreatic Fistula, Internal medicine, Pancreatic cancer, medicine, Humans, Aged, Retrospective Studies, MESH: Humans, business.industry, Retrospective cohort study, MESH: Adult, MESH: Retrospective Studies, medicine.disease, MESH: Male, Pancreatic Neoplasms, Surgery, Neoplasm Recurrence, Local, business, MESH: Female
Abstract: Objectives: The aim of this study was to assess the impact of clinically relevant postoperative pancreatic fistula (CR-POPF) on patient disease-specific survival and recurrence after curative distal pancreatectomy (DP) for pancreatic cancer. Design: This was a retrospective case-control analysis. Methods: We examined the data of adult patients with a diagnosis of pancreatic ductal adenocarcinoma (PDAC) of the body and tail of the pancreas undergoing curative DP, over a 10-year period in 12 European surgical departments, from a prospectively implemented database. Results: Among the 382 included patients, 283 met the strict inclusion criteria; 139 were males (49.1%) and the median age of the entire population was 70years (range 37–88). A total of 121 POPFs were observed (42.8%), 42 (14.9%) of which were CR-POPFs. The median follow-up period was 24months (range 3–120). Although poorer in the POPF group, overall survival (OS) and disease-free survival (DFS) did not differ significantly between patients with and without CR-POPF (p = 0.224 and p = 0.165, respectively). CR-POPF was not significantly associated with local or peritoneal recurrence (p = 0.559 and p = 0.302, respectively). A smaller percentage of patients benefited from adjuvant chemotherapy after POPF (76.2% vs. 83.8%), but the difference was not significant (p = 0.228). Conclusions: CR-POPF is a major complication after DP but it did not affect the postoperative therapeutic path or long-term oncologic outcomes. CR-POPF was not a predictive factor for disease recurrence and was not associated with an increased incidence of peritoneal or local relapse. Trial Registration: ClinicalTrials.gov ID: NCT04348084.
Published: 2020
Full Text: View/download PDF

18. mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors

Author: Antonio Daniele Pinna, Natalie Filmann, Lionel Rostaing, Jens Brockmann, Michael Heise, Andreas A. Schnitzbauer, Simone I. Strasser, Giorgio Rossi, Silvio Nadalin, Jean Gugenheim, Tom M. Ganten, Umberto Cillo, Norman M. Kneteman, Koert P. de Jong, André Roy, Víctor Sánchez Turrión, Thomas Becker, Christoph Duvoux, Markus Rentsch, Jürgen Klempnauer, Utz Settmacher, George Philippe Pageaux, Christian Klein, Roberto Troisi, Edward K. Geissler, Darius F. Mirza, Gunnar Söderdahl, Peter Neuhaus, Jan Lerut, Hans J. Schlitt, Patrizia Burra, Vincenzo Mazzaferro, Johann Pratschke, T. Scholz, Neville V. Jamieson, Wolf O. Bechstein, James Powel, Thomas Soliman, Heikki Mäkisalo, Magnus Rizell, René Adam, Bart van Hoek, Michele Colledan, Itxarone Bilbao, Philippe Bachellier, Olivier Chazoullières, Sherrie Bhoori, Jaques Pirenne, UCL - SSS/IREC - Institut de recherche expérimentale et clinique, Schnitzbauer, A, Filmann, N, Adam, R, Bachellier, P, Bechstein, W, Becker, T, Bhoori, S, Bilbao, I, Brockmann, J, Burra, P, Chazoullieres, O, Cillo, U, Colledan, M, Duvoux, C, Ganten, T, Gugenheim, J, Heise, M, van Hoek, B, Jamieson, N, de Jong, K, Klein, C, Klempnauer, J, Kneteman, N, Lerut, J, Makisalo, H, Mazzaferro, V, Mirza, D, Nadalin, S, Neuhaus, P, Pageaux, G, Pinna, A, Pirenne, J, Pratschke, J, Powel, J, Rentsch, M, Rizell, M, Rossi, G, Rostaing, L, Roy, A, Scholz, T, Settmacher, U, Soliman, T, Strasser, S, Soderdahl, G, Troisi, R, Turrion, V, Schlitt, H, Geissler, E, Universitätsklinikum Frankfurt, Centre Hépato-Biliaire [Hôpital Paul Brousse] (CHB), Hôpital Paul Brousse-Assistance Publique - Hôpitaux de Paris, Les Hôpitaux Universitaires de Strasbourg (HUS), University Medical Center of Schleswig–Holstein = Universitätsklinikum Schleswig-Holstein (UKSH), Kiel University, IRCCS Istituto Nazionale dei Tumori [Milano], Vall d'Hebron University Hospital [Barcelona], Universitätsklinikum Münster, Universita degli Studi di Padova, CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Azienda Ospedaliera di Padova, Azienda Ospedaliera Ospedale Papa Giovanni XXIII [Bergamo, Italy], Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), UniversitätsKlinikum Heidelberg, Centre Hospitalier Universitaire de Nice (CHU Nice), Leiden University Medical Center (LUMC), Cambridge University Hospitals - NHS (CUH), University of Cambridge [UK] (CAM), Addenbrooke's Hospital, Cambridge University NHS Trust, University Medical Center Groningen [Groningen] (UMCG), University of Groningen [Groningen], Universitätsklinikum Essen [Universität Duisburg-Essen] (Uniklinik Essen), Medizinische Hochschule Hannover (MHH), University of Alberta, Université Catholique de Louvain = Catholic University of Louvain (UCL), Helsinki University Hospital, University Hospitals Birmingham [Birmingham, Royaume-Uni], Queens Elizabeth Hospital [Birmingham], Universitätsklinikum Tübingen - University Hospital of Tübingen, Eberhard Karls Universität Tübingen = Eberhard Karls University of Tuebingen, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Policlinico S. Orsola-malpighi, Alma Mater Studiorum Università di Bologna [Bologna] (UNIBO)-Servizio sanitario regionale Emilia-Romagna, UZLeuven, Royal Infirmary of Edinburgh, Ludwig-Maximilians-Universität München (LMU), Sahlgrenska University Hospital [Gothenburg], Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, CHU Grenoble, Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal (UdeM), Uppsala University Hospital, Universitätsklinikum Jena [Jena], Medizinische Universität Wien = Medical University of Vienna, Royal Prince Alfred Hospital, Karolinska University Hospital [Stockholm], Ghent University Hospital, Hospital Universitario Puerta de Hierro-Majadahonda [Madrid, Spain], University Hospital Regensburg, Fraunhofer Institute for Toxicology and Experimental Medicine (Fraunhofer ITEM), Fraunhofer (Fraunhofer-Gesellschaft), Publica, Schnitzbauer, A. A., Filmann, N., Adam, R., Bachellier, P., Bechstein, W. O., Becker, T., Bhoori, S., Bilbao, I., Brockmann, J., Burra, P., Chazoullieres, O., Cillo, U., Colledan, M., Duvoux, C., Ganten, T. M., Gugenheim, J., Heise, M., van Hoek, B., Jamieson, N., de Jong, K. P., Klein, C. G., Klempnauer, J., Kneteman, N., Lerut, J., Makisalo, H., Mazzaferro, V., Mirza, D. F., Nadalin, S., Neuhaus, P., Pageaux, G. -P., Pinna, A. D., Pirenne, J., Pratschke, J., Powel, J., Rentsch, M., Rizell, M., Rossi, G., Rostaing, L., Roy, A., Scholz, T., Settmacher, U., Soliman, T., Strasser, S., Soderdahl, G., Troisi, R., Turrion, V. S., Schlitt, H. J., Geissler, E. K., Università degli Studi di Padova = University of Padua (Unipd), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Herrada, Anthony, Groningen Institute for Organ Transplantation (GIOT), and Guided Treatment in Optimal Selected Cancer Patients (GUTS)
Subjects: Male, Oncology, [SDV.MHEP.CHI] Life Sciences [q-bio]/Human health and pathology/Surgery, medicine.medical_treatment, Medizin, Liver transplantation, MESH: Intention to Treat Analysis, mTOR-inhibition, 0302 clinical medicine, MESH: Liver Neoplasms, Clinical endpoint, MESH: Carcinoma, Hepatocellular, Milan criteria, MESH: Aged, MESH: Middle Aged, Liver Neoplasms, Hazard ratio, Middle Aged, Intention to Treat Analysis, 3. Good health, Survival Rate, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, multivariate COX regression, Female, 030211 gastroenterology & hepatology, MESH: Immunosuppressive Agents, MESH: Neoplasm Recurrence, Local, Immunosuppressive Agents, medicine.drug, medicine.medical_specialty, MESH: Liver Transplantation, Carcinoma, Hepatocellular, MESH: Survival Rate, AFP, [SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery, 03 medical and health sciences, Internal medicine, medicine, Carcinoma, Humans, Survival rate, Aged, Sirolimus, MESH: Humans, business.industry, medicine.disease, digestive system diseases, MESH: Male, Liver Transplantation, Surgery, MESH: Sirolimus, Neoplasm Recurrence, Local, business, MESH: Female
Abstract: OBJECTIVE: The aim of this study was to evaluate the survival benefit of sirolimus in patients undergoing liver transplantation (LT) for hepatocellular carcinoma (HCC) (exploratory analysis of the SiLVER-trial). SUMMARY AND BACKGROUND DATA: Patients receiving LT) for HCC are at a high risk for tumor recurrence. Calcineurin inhibitors have shown evidence to promote cancer growth, whereas mammalian target of rapamycin (mTOR) inhibitors like sirolimus have anticancer effects. In the SiLVER-trial (Clinicaltrials.gov: NCT00355862), the effect of sirolimus on the recurrence of HCC after LT was investigated in a prospective randomized trial. Although the primary endpoint of improved disease-free survival (DFS) with sirolimus was not met, outcomes were improved for patients in the sirolimus-treatment arm in the first 3 to 5 years. To learn more about the key variables, a multivariate analysis was performed on the SiLVER-trial data. PATIENTS AND METHODS: Data from 508 patients of the intention-to-treat analysis were included in exploratory univariate and multivariate models for overall survival (OS), DFS and a competing risk analysis for HCC recurrence. RESULTS: Sirolimus use for ≥3 months after LT for HCC independently reduced the hazard for death in the multivariate analysis [hazard ratio (HR): 0.7 (95% confidence interval, CI: 0.52-0.96, P = 0.02). Most strikingly, patients with an alpha-fetoprotein (AFP) ≥10 ng/mL and having used sirolimus for ≥3 months, benefited most with regard to OS, DFS, and HCC-recurrence (HR: 0.49-0.59, P = 0.0079-0.0245). CONCLUSIONS: mTOR-inhibitor treatment with sirolimus for ≥3 months improves outcomes in LT for HCC, especially in patients with AFP-evidence of higher tumor activity, advocating particularly for mTOR inhibitor use in this subgroup of patients. CLINICAL TRIAL REGISTRATION: EudraCT: 2005-005362-36 CLINICALTRIALS.GOV:: NCT00355862. ispartof: ANNALS OF SURGERY vol:272 issue:5 pages:855-862 ispartof: location:United States status: published
Published: 2020
Full Text: View/download PDF

19. [Insurability and history of cancer]

Author: Bousquet, Philippe-Jean, Lafay, Lionel, Département de surveillance, d'enquête et d'évaluation des données [Boulogne Billancourt] (INCa), Institut national du cancer [Boulogne] (INCA), and Dupuis, Christine
Subjects: MESH: Humans, aeras, mortgage, [SDV]Life Sciences [q-bio], tertiary prevention, insurance policy, cancer plan, MESH: Cancer Survivors, MESH: Insurance, [SDV] Life Sciences [q-bio], Insurance, Cancer Survivors, Humans, cancer, Neoplasm Recurrence, Local, MESH: Neoplasm Recurrence, Local
Abstract: At the instigation of the Aeras convention -Insuring and borrowing with an aggravated health risk - and the 2014- 2019 Cancer Plan, the Law of 26 January 2016 introduces the « right to be forgotten » for people with cancer. Thus, people wishing to take out an insurance policy for a mortgage or consumer credit do not have to declare their cancer 10 years after the end of the therapeutic protocol, in the absence of relapse. This period is reduced to 5 years for cancers occurring before the age of 18 years. Associated with this right, the « reference grid » identifies situations for which insurance will be granted without surcharge or exclusion of guarantee, or under conditions that are close to standard conditions. This concerns both cancer -breast, thyroid, prostate cancers ...- and noncancer diseases -HIV, hepatitis C, cystic fibrosis ...-. Through his relationship with his patient, the doctor plays a key role in providing the best insight and helping him in his efforts.ASSURABILITÉ ET ANTÉCÉDENTS DE CANCER Sous l’impulsion de la convention AERAS -S’assurer et emprunter avec un risque aggravé de santé- et du Plan cancer 2014-2019, la loi de 26 janvier 2016 introduit le « droit à l’oubli » pour les personnes atteintes d’un cancer. Ainsi, les personnes souhaitant souscrire une assurance pour un prêt immobilier ou un crédit à la consommation n’ont plus à déclarer leur cancer 10 ans après la fin du protocole thérapeutique, en absence de rechute. Ce délai est ramené à 5 ans pour les cancers survenant avant l’âge de 18 ans. Associé à ce droit, la grille de référence identifie des situations pour lesquelles l’assurance sera accordée sans surprime ni exclusion de garantie, ou dans des conditions se rapprochant des conditions standard. Cela concerne à la fois des pathologies cancéreuses -cancer du sein, de la thyroïde, de la prostate…- et non cancéreuses -infection par le virus de l’immunodéficience humaine, hépatite C, mucoviscidose…-. Du fait de sa relation avec son patient, le médecin joue un rôle clé en l’éclairant au mieux et en l’aidant dans ses démarches.
Published: 2019

20. Common origin of sequential cutaneous CD30+ lymphoproliferations with nodal involvement evidenced by genome-wide clonal evolution

Author: José Adélaïde, Max Chaffanet, Nadine Carbuccia, Anne Murati, Reda Bouabdallah, Lénaïg Mescam, Morgan Avenin, Daniel Birnbaum, Luc Xerri, Diane Coso, Sebastien Taix, François Bertucci, Séverine Garnier, N. Bonnet, Arnaud Guille, Département de Biopathologie, Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Aix-Marseille Université - Faculté de médecine (AMU MED), Aix Marseille Université (AMU), Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Service d'Hématologie, Aix Marseille Université (AMU)-Institut Paoli-Calmettes, and Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Subjects: 0301 basic medicine, Histology, CD30, [SDV]Life Sciences [q-bio], diffuse large B-cell lymphoma, Context (language use), MESH: Lymph Nodes, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, Biology, Somatic evolution in cancer, MESH: Clonal Evolution, Pathology and Forensic Medicine, 03 medical and health sciences, 0302 clinical medicine, cutaneous anaplastic large-cell lymphoma, immune system diseases, hemic and lymphatic diseases, medicine, Lymphomatoid papulosis, Gene, Lymph node, MESH: Humans, MESH: Middle Aged, MESH: Skin Neoplasms, MESH: Lymphomatoid Papulosis, General Medicine, medicine.disease, lymphomatoid papulosis, MESH: Male, Lymphoma, 030104 developmental biology, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Cancer research, MESH: Lymphoma, Large B-Cell, Diffuse, MESH: Disease Progression, MESH: Lymphoma, Large-Cell, Anaplastic, Diffuse large B-cell lymphoma, MESH: Neoplasm Recurrence, Local
Abstract: AIMS This study sought to clarify the molecular pathways underlying the putative evolution from lymphomatoid papulosis (LyP) to cutaneous anaplastic large-cell lymphoma (c-ALCL) and lymph node invasion (LNI). METHODS AND RESULTS We analysed nine sequential tumours from the same patient presenting with parallel evolution of LyP (n = 3) and c-ALCL (n = 1) with LNI (n = 1), combined with systemic diffuse large B-cell lymphoma (DLBCL) (n = 4). Clonality analysis showed a common clonal T-cell origin in the five CD30+ lesions, and a common clonal B-cell origin in the four DLBCL relapses. Array-comparative genomic hybridisation and targeted next-generation sequencing analysis demonstrated relative genomic stability of LyP lesions as compared with clonally related anaplastic large-cell lymphoma (ALCL) tumours, which showed 4q and 22q13 deletions involving the PRDM8 and TIMP3 tumour suppressor genes, respectively. The three analysed CD30+ lesions showed mostly private (specific to each sample) genetic alterations, suggesting early divergence from a common precursor. In contrast, DLBCL tumours showed progressive accumulation of private alterations, indicating late divergence. CONCLUSIONS Sequential cutaneous and nodal CD30+ tumours were clonally related. This suggests that LyP, c-ALCL and LNI represent a continuous spectrum of clonal evolution emerging from a common precursor of cutaneous CD30+ lymphoproliferations. Therefore, nodal ALCL tumours in the context of LyP should be considered as a form of transformation rather than composite lymphoma.
Published: 2019
Full Text: View/download PDF

21. Pièce opératoire ypT0N0 après séquence chimiothérapie néo-adjuvante – cystectomie pour TVIM : épidémiologie et impact pronostique. Une mise au point du CCAFU Vessie

Author: Pignot, G., Houédé, N., Roumiguié, M., Audenet, F., Brunelle, S., Colin, P., Comperat, E., Larre, S., Masson-Lecomte, A., Neuzillet, Y., Xylinas, E., Méjean, A., Roupret, M., Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Hôpital de Rangueil, CHU Toulouse [Toulouse], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Hôpital Privé La Louvière, Service d'anatomie pathologique [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Universitaire de Reims (CHU Reims), Hôpital Foch [Suresnes], AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Pitié-Salpêtrière [AP-HP], and Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Subjects: MESH: Tumor Burden, MESH: Combined Modality Therapy, Neoplasm, Residual, Survival, MESH: Societies, Medical, MESH: Neoadjuvant Therapy, Urinary Bladder, [SDV.CAN]Life Sciences [q-bio]/Cancer, Cystectomy, Medical Oncology, MESH: Prognosis, MESH: Urinary Bladder, Antineoplastic Combined Chemotherapy Protocols, Pronostic, Chemotherapy, Humans, MESH: Incidence, MESH: Neoplasm, Residual, MESH: Muscle Neoplasms, Societies, Medical, MESH: Medical Oncology, Neoplasm Staging, MeSH, MESH: Carcinoma, Transitional Cell, Carcinoma, Transitional Cell, Muscle Neoplasms, MESH: Humans, Incidence, Bladder cancer, MESH: Cystectomy, MESH: Neoplasm Staging, Prognosis, Combined Modality Therapy, Cancer de la vessie, Neoadjuvant Therapy, MESH: Urinary Bladder Neoplasms, Tumor Burden, MESH: France, MESH: Antineoplastic Combined Chemotherapy Protocols, Urinary Bladder Neoplasms, Survie, France, Neoplasm Recurrence, Local, MESH: Neoplasm Recurrence, Local, Chimiothérapie, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: International audience; INTRODUCTION:Neoadjuvant chemotherapy (NAC) is recommended for localized muscle-invasive bladder cancer when patients are fit for cisplatin-based chemotherapy. A pathological complete response can be observed, corresponding to ypT0N0 stage on the radical cystectomy specimen. This review discusses the incidence, prognosis and potential therapeutic impact of complete response on pathological specimen in NAC treated patients.METHODS:A comprehensive review of the literature was conducted using Medline database, with no time frame. The articles were selected using the following keywords association: "Bladder cancer" (Mesh) AND "Neoadjuvant chemotherapy" (Mesh) AND "pT0" (Mesh).RESULTS:After NAC, ypT0N0 rates vary from 9 to 46% among the series, reported rates that are higher compared to those of pT0 without NAC administration. The incidence depends on the chemotherapy regimen (maximal local effect with cisplatin-based chemotherapy) and the pathological type of the disease (presence of variant histologies). Molecular analyses of bladder cancer could probably help in the near future to identify and predict NAC responders. Pathological complete response is associated with a favorable prognosis in terms of recurrence-free and overall survival. Nevertheless, disease recurrences are still observed in 10-15% of cases, which underlies the importance of local treatment and close follow-up even in these patients.CONCLUSION:ypT0N0 rate is approximately 25% after NAC, that is 4.3 higher than after bladder resection alone. The prognosis is better than that with residual tumor on specimen and is comparable to that of pT0 without NAC administration.
Published: 2018
Full Text: View/download PDF

22. Quality of life and female sexual function after skinning vulvectomy with split-thickness skin graft in women with vulvar intraepithelial neoplasia or vulvar Paget disease

Author: Eric Watier, Karine Morcel, Sébastien Henno, Jean Levêque, Habiba Mesbah, A. Lemarrec, Vincent Lavoué, N. Bertheuil, Service de Gynécologie et Obstétrique [Rennes] = Gynaecology [Rennes], CHU Pontchaillou [Rennes], CRLCC Eugène Marquis (CRLCC), Service de chirurgie plastique, reconstructive et esthétique [Rennes] = Cosmetic Reconstructive and Plastic surgery [Rennes], Service d'anatomie et cytologie pathologiques [Rennes] = Anatomy and Cytopathology [Rennes], and Le Corre, Morgane
Subjects: MESH: Sexual Behavior, medicine.medical_treatment, MESH: Paget Disease, Extramammary, 0302 clinical medicine, Quality of life, Surveys and Questionnaires, MESH: Aged, education.field_of_study, MESH: Middle Aged, 030219 obstetrics & reproductive medicine, Vulvar Neoplasms, Incidence (epidemiology), Skin Transplantation, General Medicine, Middle Aged, Vulvar Paget disease, 3. Good health, Paget Disease, Extramammary, Oncology, 030220 oncology & carcinogenesis, Vulvectomy, Population study, Female, MESH: Neoplasm Recurrence, Local, Carcinoma in Situ, Adult, Skin graft, medicine.medical_specialty, Sexual Behavior, Population, Disease-Free Survival, 03 medical and health sciences, Vulvar intraepithelial neoplasia, medicine, Humans, education, Aged, Retrospective Studies, MESH: Carcinoma in Situ, MESH: Humans, business.industry, MESH: Questionnaires, MESH: Quality of Life, MESH: Adult, MESH: Retrospective Studies, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Retrospective cohort study, medicine.disease, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, MESH: Vulvar Neoplasms, Surgery, MESH: Disease-Free Survival, MESH: Skin Transplantation, Neoplasm Recurrence, Local, Sexual function, business, MESH: Female
Abstract: International audience; OBJECTIVE: Vulvar intraepithelial neoplasia (VIN) and vulvar Paget disease are managed with either vulvectomy, destructive treatments (laser, antimitotic drugs) or immunostimulants. All these options are associated with functional complications. The purpose of this study was to evaluate the surgical technique consisting of skinning vulvectomy with split-thickness skin graft, and its effect on overall quality of life and sexual function. METHODS: A retrospective study was conducted on thirteen patients who underwent skinning vulvectomy with split-thickness skin graft between 1999 and 2009. Overall quality of life and sexual function were assessed with the Medical Outcome Study Short Form 36 (MOS SF-36) and Female Sexual Function Index (FSFI), respectively. RESULTS: The median age of patients was 54 (range: 33-77) years. Three patients had Paget disease and 10 patients had VIN lesions. The excision margins were clear in 46% of cases. The incidence of occult cancer was 31%. The mean follow-up period was 77 (±35) months. Four patients experienced a relapse of their intraepithelial disease. The mean disease-free survival was 58 (±44) months. There was no significant difference in MOS SF-36 scores between the study population and the general population. The patients assessed with the FSFI regained normal sexual function after the surgical procedure. CONCLUSION: Skinning vulvectomy with split-thickness skin graft is a feasible technique yielding good results in terms of quality of life and sexual function. It enables occult cancer to be diagnosed in patients with VIN or Paget disease.
Published: 2013
Full Text: View/download PDF

23. Results From a Prospective, Open-Label, Phase II Trial of Bendamustine in Refractory or Relapsed T-Cell Lymphomas: The BENTLY Trial

Author: Arnaud Jaccard, Momar Diouf, Gandhi Damaj, Thierry Lamy, Pascale Cony-Makhoul, Krimo Bouabdallah, Bertrand Joly, Roch Houot, Guillaume Cartron, Steven Le Gouill, Emmanuel Gyan, Remy Gressin, Jean-Pierre Vilque, Bachra Choufi, Marie-Christine Béné, Sophie Park, Michael Bubenheim, Laurence Sanhes, Aline Schmidt-Tanguy, Laurent Voillat, Jean-Marc Schiano-de Collela, Anne Banos, Alain Saad, Olivier Tournilhac, Jean-Pierre Marolleau, Antoine Martin, CHU Amiens-Picardie, Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Bordeaux [Bordeaux], CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hôpital Duchenne, CH Boulogne sur Mer, CIC - Tours, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital de Bayonne, Centre Hospitalier de la Côte Basque (CHCB), CHU Limoges, Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Clermont-Ferrand, Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre Hospitalier Chalon-sur-Saône William Morey, Hôpital Sud-Fancilien, CH Sud-Fancilien, Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Hôpital de Béziers, CH Béziers, Centre Hospitalier d'Annecy, Centre hospitalier d'Annecy, Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN), Hôpital de Perpignan, Centre Hospitalier Saint Jean de Perpignan, CHU Rouen, Normandie Université (NU), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Hôpital Avicenne [AP-HP], Institut National de la Santé et de la Recherche Médicale (INSERM)-EFS-CHU Grenoble-Université Joseph Fourier - Grenoble 1 (UJF), CH de la Côte Basque, UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU), and Le Corre, Morgane
Subjects: Male, MESH: Remission Induction, Cancer Research, medicine.medical_treatment, Salvage therapy, MESH: Antineoplastic Agents, Alkylating, Gastroenterology, MESH: Aged, 80 and over, 0302 clinical medicine, Bendamustine Hydrochloride, Prospective Studies, Aged, 80 and over, MESH: Aged, education.field_of_study, MESH: Middle Aged, Remission Induction, MESH: Neoplasm Staging, MESH: Follow-Up Studies, Middle Aged, MESH: Lymphoma, T-Cell, Peripheral, Prognosis, MESH: Drug Resistance, Neoplasm, MESH: Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Cutaneous, MESH: Salvage Therapy, 3. Good health, Survival Rate, Oncology, 030220 oncology & carcinogenesis, Nitrogen Mustard Compounds, Female, MESH: Neoplasm Recurrence, Local, medicine.drug, Adult, Bendamustine, medicine.medical_specialty, MESH: Survival Rate, Population, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, Neutropenia, MESH: Prognosis, 03 medical and health sciences, Refractory, Internal medicine, [SDV.BBM] Life Sciences [q-bio]/Biochemistry, Molecular Biology, medicine, Humans, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, education, Antineoplastic Agents, Alkylating, [SDV.BC] Life Sciences [q-bio]/Cellular Biology, Survival rate, Aged, Neoplasm Staging, Salvage Therapy, Chemotherapy, MESH: Humans, business.industry, MESH: Nitrogen Mustard Compounds, Lymphoma, T-Cell, Peripheral, MESH: Adult, medicine.disease, MESH: Male, MESH: Prospective Studies, Lymphoma, Surgery, Drug Resistance, Neoplasm, Neoplasm Recurrence, Local, business, MESH: Female, Follow-Up Studies, 030215 immunology
Abstract: Purpose To determine the efficacy and safety of bendamustine as a single agent in refractory or relapsed T-cell lymphomas. Patients and Methods Patients with histologically confirmed peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma who progressed after one or more lines of prior chemotherapy received bendamustine at 120 mg/m2 per day on days 1 through 2 every 3 weeks for six cycles. The primary end point was overall response rate (ORR). Secondary end points were duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Results Of the 60 patients included, 27 (45%) were refractory to their last prior chemotherapy, and the median duration of the best previous response was 6.6 months. Histology was predominantly angioimmunoblastic lymphadenopathy and PTCL not otherwise specified. The disease was disseminated in the majority of patients (87%). The median number of previous lines of chemotherapy was one (range, one to three). Twenty patients (33%) received fewer than three cycles of bendamustine, mostly because of disease progression. In the intent-to-treat population, the ORR was 50%, including complete response in 17 patients (28%) and partial response in 13 patients (22%). Bendamustine showed consistent efficacy independent of major disease characteristics. The median values for DoR, PFS, and OS were 3.5, 3.6, and 6.2 months, respectively. The most frequent grade 3 to 4 adverse events were neutropenia (30%), thrombocytopenia (24%), and infections (20%). Conclusion Bendamustine showed an encouraging high response rate across the two major PTCL subtypes, independent of age and prior treatment, with acceptable toxicity in refractory or relapsed T-cell lymphoma.
Published: 2013
Full Text: View/download PDF

24. [Radiotherapy for soft tissue sarcomas: Technical evolution and impact on clinical benefit]

Author: C, Llacer-Moscardo, C, Bourgier, A, Morel, P, Fenoglietto, S, Carrère, N, Firmin, D, Azria, Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Service de radiothérapie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Département de chirurgie, CRLCC Val d'Aurelle - Paul Lamarque, and Département d'oncologie Médicale
Subjects: MESH: Radiotherapy, Adjuvant, MESH: Margins of Excision, Contrôle local, MESH: Neoadjuvant Therapy, Soft Tissue Neoplasms, [SDV.CAN]Life Sciences [q-bio]/Cancer, Fractures, Bone, Toxicité, Edema, Humans, MESH: Patient Selection, IMRT, MESH: Radiotherapy Dosage, Soft tissue sarcoma, MESH: Humans, Toxicity, Patient Selection, Margins of Excision, MESH: Fractures, Bone, Radiotherapy Dosage, Sarcoma, MESH: Radiotherapy, Intensity-Modulated, Neoadjuvant Therapy, RCMI, MESH: Edema, Local control, MESH: Sarcoma, Radiotherapy, Adjuvant, Radiotherapy, Intensity-Modulated, Neoplasm Recurrence, Local, MESH: Neoplasm Recurrence, Local, MESH: Radiotherapy, Image-Guided, Sarcomes des tissus mous, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Radiotherapy, Image-Guided, MESH: Soft Tissue Neoplasms
Abstract: International audience; The standard treatment for extremity soft tissue sarcomas is based on the association of surgery and radiotherapy. This strategy allows local control improvement with the risk of increased toxicity. There is therefore a growing interest to identify those patients who will benefit from radiotherapy and those who will have the same local control with surgery alone. Furthermore, the development of toxicity has been correlated with the extension of the irradiated volume and the volume receiving high doses. Technological development as intensity modulated radiotherapy and image-guided radiotherapy allows limited irradiated volume improving the protection of the organs at risk leading to clinical benefit improvement. Moreover, efforts are being done to improve local control for the patients at high risk of local relapse. In this paper, we discuss all these mentioned aspects.
Published: 2016
Full Text: View/download PDF

25. Current standards and new innovative approaches for treatment of pancreatic cancer

Author: Jean-Luc Van Laethem, Michel Ducreux, Ahmet Ayav, Florence Huguet, Jean-Baptiste Bachet, Caroline Caramella, Aurélien Lambert, Raphaël Maréchal, Thierry Conroy, Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université Paris Descartes - Paris 5 (UPD5)-Université de Lorraine (UL), Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), UNICANCER, Service d'Hépato-Gastro-Entérologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Chirurgie Digestive Hépatobiliaire et Endocrine [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service d'oncologie-radiothérapie [CHU Tenon], CHU Tenon [AP-HP], Institut Gustave Roussy (IGR), Service de Gastro-Entérologie, d'Hépato-Pancréatologie et d'Oncologie Digestive - Endoscopie Digestive (hôpital Erasme), Hôpital Erasme [Bruxelles] (ULB), Faculté de Médecine [Bruxelles] (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB)-Faculté de Médecine [Bruxelles] (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB), Institut de Cancérologie de Lorraine - Alexis Vautrin (ICL), Service d'Hépato-Gastroentérologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Service d’Oncologie-Radiothérapie [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Tenon [APHP], and Université Libre de Bruxelles [Bruxelles] (ULB)-Hôpital Erasme (Bruxelles)
Subjects: 0301 basic medicine, Oncology, Cancer Research, Palliative care, Staging, FOLFIRINOX, medicine.medical_treatment, MESH: Therapies, Investigational, Targeted therapy, Imaging, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, MESH: Molecular Targeted Therapy, Molecular Targeted Therapy, Precision Medicine, Neoadjuvant therapy, Therapies, Investigational, Palliative Care, MESH: Neoplasm Staging, Reference Standards, Neoadjuvant Therapy, 3. Good health, MESH: Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Adjuvant, MESH: Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, MESH: Palliative Care, MESH: Reference Standards, MESH: Pancreatic Neoplasms, MESH: Neoplasm Recurrence, Local, medicine.drug, Diagnostic Imaging, medicine.medical_specialty, MESH: Neoadjuvant Therapy, Adenocarcinoma, MESH: Precision Medicine, 03 medical and health sciences, Pancreatic cancer, Internal medicine, medicine, Humans, Chemotherapy, Survival rate, Neoplasm Staging, MESH: Humans, Radiotherapy, business.industry, MESH: Diagnostic Imaging, MESH: Adenocarcinoma, medicine.disease, Gemcitabine, Pancreatic Neoplasms, Radiation therapy, 030104 developmental biology, Surgery, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Neoplasm Recurrence, Local, business
Abstract: International audience; Pancreatic adenocarcinoma remains a devastating disease with a 5-year survival rate not exceeding 6%. Treatment of this disease remains a major challenge. This article reviews the state-of-the-art in the management of this disease and the new innovative approaches that may help to accelerate progress in treating its victims. After careful pre-therapeutic evaluation, only 15-20% of patients diagnosed with a pancreatic cancer (PC) are eligible for upfront radical surgery. After R0 or R1 resection in such patients, evidence suggests a significantly positive impact on survival of adjuvant chemotherapy comprising 6 months of gemcitabine or fluorouracil/folinic acid. Delayed adjuvant chemoradiation is considered as an option in cases of positive margins. Borderline resectable pancreatic cancer (BRPC) is defined as a tumour involving the mesenteric vasculature to a limited extend. Resection of these tumours is technically feasible, yet runs the high risk of a R1 resection. Neoadjuvant treatment probably offers the best chance of achieving successful R0 resection and long-term survival, but the best treatment options should be determined in prospective randomised studies. Gemcitabine has for 15 years been the only validated therapy for advanced PC. Following decades of negative phase III studies, increasing evidence now suggests that further significant improvements to overall survival can be achieved via either Folfirinox or gemcitabine + nab-paclitaxel regimens. Progress in systemic therapy may improve the chances of resection in borderline resectable pancreatic cancer (BRPC) or locally advanced PC. This requires first enhancing knowledge of the genetic events driving carcinogenesis, which may then be translated into clinical studies.
Published: 2016
Full Text: View/download PDF

26. Regulatory B lymphocyte functions should be considered in chronic lymphocytic leukemia

Author: Jacques-Olivier Pers, Yves Renaudineau, Anne Bordron, Audrey Mohr, Christophe Jamin, Cristina Bagacean, Lymphocyte B et Auto-immunité (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), LabEX IGO Immunothérapie Grand Ouest, Laboratoire d'Immunologie et Immunothérapie, and Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)
Subjects: 0301 basic medicine, Lymphocyte, Regulatory B cells, Chronic lymphocytic leukemia, medicine.medical_treatment, Immunology, regulatory B cell, Review, Biology, Secondary lymphoid organs, 03 medical and health sciences, 0302 clinical medicine, Immune system, immune system diseases, hemic and lymphatic diseases, medicine, Immunology and Allergy, MESH: Leukemia, Lymphocytic, Chronic, B-Cell, MESH: Humans, MESH: Middle Aged, Immunotherapy, medicine.disease, Phenotype, MESH: Male, 030104 developmental biology, medicine.anatomical_structure, Oncology, [SDV.IMM]Life Sciences [q-bio]/Immunology, Bone marrow, immunotherapy, MESH: Heart Neoplasms, MESH: Neoplasm Recurrence, Local, CLL, 030215 immunology, B lymphocytes
Abstract: International audience; Chronic lymphocytic leukemia (CLL) is characterized by an abnormal expansion of mature B cells in the bone marrow and their accumulation in blood and secondary lymphoid organs. Tumor CLL cells share expression of various surface molecules with many subsets of B cells and have several common characteristics with regulatory B cells (B regs). However, the identification of B regs and their role in CLL remain elusive. The aim of this review is to summarize recent works regarding the regulatory and phenotypic characteristic of B regs and their associated effects on the immune system. It is also meant to highlight their potential importance with regards to the immunotherapeutic response.
Published: 2016

27. Outcome of Acute Promyelocytic Leukemia (APL) in Children and Adolescents: An Analysis in Two Consecutive Trials of the European APL Group

Author: Xavier Thomas, Christian Recher, Hervé Dombret, Agnès Guerci, Norbert Vey, Bruno Cassinat, André Baruchel, Nadia Idres, Thierry Leblanc, Pierre Fenaux, Christine Chomienne, Miguel A. Sanz, Guy Leverger, Cecile Bally, Lionel Ades, Yves Bertrand, Alain Robert, Jehane Fadlallah, Emmanuel Raffoux, Sciences Po Grenoble - Institut d'études politiques de Grenoble (IEPG), Service d'hématologie-immunologie-oncologie pédiatrique [CHU Trousseau], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Service d'hématologie biologique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Service de Pédiatrie Hématologique, Hôpital Robert Debré, Unite de Biologie Cellulaire, Hematology (IPC-Marseille), Hématologie -Immunologie -Cibles thérapeutiques, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Lymphocyte et cancer, IFR105-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Avicenne [AP-HP], Service d'hématologie clinique [Avicenne], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris 13 (UP13)-Hôpital Avicenne [AP-HP]
Subjects: Male, Cancer Research, Pediatrics, Time Factors, medicine.medical_treatment, MESH: Risk Assessment, MESH: Dose-Response Relationship, Drug, law.invention, MESH: Cause of Death, 0302 clinical medicine, Leukemia, Promyelocytic, Acute, Randomized controlled trial, law, MESH: Child, Cause of Death, Antineoplastic Combined Chemotherapy Protocols, Medicine, Cumulative incidence, Child, MESH: Treatment Outcome, Cause of death, MESH: Middle Aged, Age Factors, Middle Aged, Prognosis, 3. Good health, Europe, MESH: Antineoplastic Combined Chemotherapy Protocols, Leukemia, Treatment Outcome, Oncology, MESH: Survival Analysis, Child, Preschool, 030220 oncology & carcinogenesis, Female, MESH: Neoplasm Recurrence, Local, Adult, Acute promyelocytic leukemia, medicine.medical_specialty, Adolescent, [SDV.CAN]Life Sciences [q-bio]/Cancer, Tretinoin, MESH: Drug Administration Schedule, Risk Assessment, MESH: Prognosis, Disease-Free Survival, Drug Administration Schedule, 03 medical and health sciences, Humans, Survival analysis, MESH: Adolescent, MESH: Age Factors, Chemotherapy, MESH: Humans, MESH: Tretinoin, Dose-Response Relationship, Drug, business.industry, MESH: Time Factors, MESH: Child, Preschool, MESH: Adult, medicine.disease, Survival Analysis, MESH: Male, Clinical trial, MESH: Disease-Free Survival, MESH: Europe, Neoplasm Recurrence, Local, business, MESH: Female, MESH: Leukemia, Promyelocytic, Acute, 030215 immunology
Abstract: Purpose Acute promyelocytic leukemia (APL) is rare in children. All-trans-retinoic acid (ATRA) combined with chemotherapy, the reference treatment of APL, is generally considered to produce similar results in children and adults. However, previously published childhood APL studies have generally analyzed all patients age < 18 years as a group, without further dividing according to age. Patients and Methods We compared disease characteristics and outcomes of children (age ≤ 12 years), adolescents (13 to 18 years), and adults (> 18 years) included in two multicenter APL clinical trials (APL 93 and 2000 trials). Results Of the 833 patients age ≤ 60 years included in the two trials, 26 (3%), 58 (7%), and 749 (90%) were children, adolescents, and adults, respectively. Children had significantly higher baseline WBC counts (P < .001). The complete remission (CR) rate (92%, 100%, and 94.5%, respectively) and 5-year cumulative incidence of relapse (CIR; 28%, 20%, and 23%, respectively) did not differ between children, adolescents, and adults, whereas adolescents had significantly better overall survival (OS; 5-year OS, 93.6% v 80.4% in adults and 80.4% in children; P = .03). However, in children age ≤ 4 years, the 5-year CIR was 52%, compared with 17.6% in children age 5 to 12 years (P = .006), although most of the younger children who relapsed experienced durable salvage with autologous or allogeneic stem-cell transplantation. Conclusion Adolescents and children age > 4 years with APL treated with ATRA and chemotherapy have outcomes at least as favorable as those of adults. Younger children seem to experience more relapses and may require reinforcement of first-line treatment.
Published: 2012
Full Text: View/download PDF

28. Prognostic Value of Extranodal Extension and Other Lymph Node Parameters in Patients With Upper Tract Urothelial Carcinoma

Author: Jay D. Raman, Thomas F. Chromecki, Eugene K. Cha, Christian Seitz, Gerhard Donner, Harun Fajkovic, Claudio Jeldres, Karim Bensalah, Vitaly Margulis, Armin Pycha, Mesut Remzi, Giacomo Novara, Alon Z. Weizer, Yair Lotan, Wassim Kassouf, Vincenzo Ficarra, Kazumasa Matsumoto, Eiji Kikuchi, Francesco Montorsi, Marco Roscigno, Pierre I. Karakiewicz, Douglas S. Scherr, Eckart Breinl, Shahrokh F. Shariat, Weill Medical College of Cornell University [New York], Cancer Prognostics and Health Outcomes Unit, Université de Montréal (UdeM), Department of Urology, University of Texas Southwestern Medical Center [Dallas]- The University of Texas Health Science Center at Houston (UTHealth), Departement of Oncological and Surgical Sciences, Universita degli Studi di Padova, Service d'urologie [Rennes] = Urology [Rennes], Hôpital Pontchaillou-CHU Pontchaillou [Rennes], University of Michigan [Ann Arbor], University of Michigan System, Keio University School of Medicine [Tokyo, Japan], Hospital Weinviertel-Korneuburg-Landesklinikum Korneuburg, General Hospital of Bolzano, Health Robotics S.r.l., Department of urology, Università Vita-Salute San Raffaele, Service d'urologie [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Fajkovic, Harun, Cha Eugene, K., Jeldres, Claudio, Donner, Gerhard, Chromecki Thomas, F., Margulis, Vitaly, Novara, Giacomo, Lotan, Yair, Raman Jay, D., Kassouf, Wassim, Seitz, Christian, Bensalah, Karim, Weizer, Alon, Kikuchi, Eiji, Roscigno, Marco, Remzi, Mesut, Matsumoto, Kazumasa, Breinl, Eckart, Pycha, Armin, Ficarra, Vincenzo, Montorsi, Francesco, Karakiewicz Pierre, I., Scherr Douglas, S., and Shariat Shahrokh, F.
Subjects: Male, Oncology, MESH: Chi-Square Distribution, urothelial carcinoma carcinoma, MESH: Lymphatic Metastasis, medicine.medical_treatment, 030232 urology & nephrology, carcinoma, Nephrectomy, lymph node excision, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, MESH: Proportional Hazards Models, neoplasm metastasis, 0302 clinical medicine, Risk Factors, MESH: Risk Factors, MESH: Ureteral Neoplasms, Stage (cooking), Lymph node, Neoadjuvant therapy, MESH: Treatment Outcome, MESH: Statistics, Nonparametric, MESH: Follow-Up Studies, MESH: Neoplasm Staging, Prognosis, MESH: Urinary Bladder Neoplasms, 3. Good health, Treatment Outcome, medicine.anatomical_structure, Chemotherapy, Adjuvant, MESH: Chemotherapy, Adjuvant, Lymphatic Metastasis, 030220 oncology & carcinogenesis, Female, [SDV.IB]Life Sciences [q-bio]/Bioengineering, Lymph, Radiology, MESH: Neoplasm Recurrence, Local, medicine.medical_specialty, Urology, urinary tract, urothelium, Statistics, Nonparametric, MESH: Prognosis, 03 medical and health sciences, Internal medicine, medicine, Carcinoma, Humans, Neoplasm Staging, Proportional Hazards Models, Retrospective Studies, Chi-Square Distribution, MESH: Humans, Ureteral Neoplasms, MESH: Lymph Node Excision, business.industry, Carcinoma in situ, MESH: Retrospective Studies, Retrospective cohort study, medicine.disease, MESH: Male, MESH: Nephrectomy, Urinary Bladder Neoplasms, Neoplasm Recurrence, Local, business, MESH: Female, Follow-Up Studies
Abstract: International audience; PURPOSE: We assessed the prognostic value of extranodal extension and other lymph node parameters in a large multicenter cohort of patients with lymph node metastasis after radical nephroureterectomy. MATERIALS AND METHODS: We retrospectively analyzed the records of 222 patients with lymph node metastasis treated with radical nephroureterectomy for upper tract urothelial carcinoma without neoadjuvant therapy. Each lymph node metastasis was microscopically evaluated for extranodal extension. RESULTS: A median of 4 lymph nodes (IQR 8) was removed. Two lymph nodes (IQR 2) were positive. Lymph node density was 51.3% (IQR 71.7%). Overall 110 patients (49.5%) had extranodal extension, which was associated with more advanced pT stage (p = 0.026). On multivariable analysis extranodal extension was associated with disease recurrence (p = 0.01) and cancer specific mortality (p = 0.013). When stratified by a 30% cutoff, lymph node density was associated with disease recurrence and cancer specific mortality on univariable but not multivariable analysis (p = 0.048 and 0.049, respectively). Adding extranodal extension to a multivariable model including pT stage and tumor architecture improved predictive accuracy for disease recurrence from 70.3% to 74.5% (p
Published: 2012
Full Text: View/download PDF

29. The Impact of Tumor Multifocality on Outcomes in Patients Treated With Radical Nephroureterectomy

Author: Vitaly Margulis, Wassim Kassouf, Alon Z. Weizer, Armin Pycha, Thomas J. Walton, Richard Zigeuner, Yair Lotan, Karl Pummer, Vincenzo Ficarra, Harun Fajkovic, Pierre I. Karakiewicz, Kazumasa Matsumoto, Douglas S. Scherr, Eiji Kikuchi, Thomas F. Chromecki, Eugene K. Cha, Mesut Remzi, Jay D. Raman, Shahrokh F. Shariat, Marco Roscigno, Giacomo Novara, Karim Bensalah, Weill Medical College of Cornell University [New York], Department of Urology, University of Texas Southwestern Medical Center [Dallas]- The University of Texas Health Science Center at Houston (UTHealth), Service d'urologie [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], University of Michigan [Ann Arbor], University of Michigan System, Keio University School of Medicine [Tokyo, Japan], Hospital Weinviertel-Korneuburg-Landesklinikum Korneuburg, General Hospital of Bolzano, Health Robotics S.r.l., Cancer Prognostics and Health Outcome Unit, Université de Montréal (UdeM), Medical University Graz, Service d'urologie [Rennes] = Urology [Rennes], and Hôpital Pontchaillou-CHU Pontchaillou [Rennes]
Subjects: Male, MESH: Carcinoma, Oncology, Survival, Lymphovascular invasion, 030232 urology & nephrology, Urinary tract cancer, Nephrectomy, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, MESH: Aged, 80 and over, 0302 clinical medicine, Interquartile range, MESH: Ureteral Neoplasms, Lymph node, MESH: Treatment Outcome, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, Radical nephroureterectomy, Hazard ratio, radical nephroureterectomy, urothelial carcinoma, Cancer-specific survival, Multifocal, Middle Aged, Prognosis, Kidney Neoplasms, 3. Good health, Survival Rate, Treatment Outcome, medicine.anatomical_structure, MESH: Ureter, 030220 oncology & carcinogenesis, Disease Progression, Female, Urothelial carcinoma, MESH: Disease Progression, [SDV.IB]Life Sciences [q-bio]/Bioengineering, MESH: Neoplasm Recurrence, Local, Renal pelvis, medicine.medical_specialty, MESH: Survival Rate, Urology, MESH: Prognosis, 03 medical and health sciences, Internal medicine, medicine, Humans, Survival rate, Aged, Retrospective Studies, MESH: Humans, Bladder cancer, Performance status, Ureteral Neoplasms, business.industry, Carcinoma, MESH: Retrospective Studies, medicine.disease, MESH: Male, MESH: Nephrectomy, Neoplasm Recurrence, Local, Ureter, MESH: Kidney Neoplasms, business, MESH: Female
Abstract: International audience; BACKGROUND: The prognostic impact of multifocal upper-tract urothelial carcinoma (UTUC) is poorly understood. OBJECTIVE: To investigate the association between tumor multifocality and clinicopathologic features and outcomes of UTUC in patients managed by radical nephroureterectomy (RNU). DESIGN, SETTING, AND PARTICIPANTS: The study included 2492 patients treated with either open or laparoscopic RNU. Tumor and patient characteristics included tumor stage, tumor grade, lymph node status, lymphovascular invasion (LVI), tumor architecture, tumor location, unifocal or multifocal disease, gender, age, history of bladder cancer (BCa), Eastern Cooperative Oncology Group (ECOG) performance status (PS), and adjuvant chemotherapy. tumor multifocality of UTUC was defined as the synchronous presence of multiple tumors in the renal pelvis or ureter. INTERVENTION: All patients were treated with either open or laparoscopic RNU. MEASUREMENTS: Univariable and multivariable models tested the effect of tumor multifocality on disease progression and cancer-specific mortality. RESULTS AND LIMITATIONS: Five hundred ninety patients (23.7%) had tumor multifocality at the time of RNU. The median follow-up was 45 mo (interquartile range [IQR]: 0-101). Tumor multifocality was significantly associated with a history of previous BCa (p=0.032), lymph node involvement (p=0.036), tumor location in the ureter (p=0.003), higher tumor stage (p
Published: 2012
Full Text: View/download PDF

30. The Diagnostic and Prognostic Performance of Urinary FGFR3 Mutation Analysis in Bladder Cancer Surveillance: A Prospective Multicenter Study

Author: Idir Ouzaid, Vincent Ravery, Pierre Mongiat-Artus, Morgan Rouprêt, Bernard Grandchamp, Calin Ciofu, Camille Couffignal, Véronique Phé, Olivier Cussenot, François Desgrandchamps, Florence Tubach, Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Urologie [CHU Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d’urologie, hôpital Bichat-Claude-Bernard, Hôpitaux Universitaires Paris Nord Val de Seine, Institut Universitaire de Cancérologie [Paris] (IUC), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Service d'Urologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'urologie [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Epidémiologie Clinique et Evaluation Economique Appliquées aux Populations Vulnérables (ECEVE (U1123 / UMR_S_1123)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Couffignal, Camille, Service d'Urologie [CHU Tenon], and CHU Tenon [AP-HP]
Subjects: Male, Time Factors, [SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, DNA Mutational Analysis, Urine, MESH: Aged, 80 and over, Medicine, Prospective Studies, MESH: DNA Mutational Analysis, Prospective cohort study, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, medicine.diagnostic_test, Cystoscopy, MESH: Follow-Up Studies, Middle Aged, [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences, Prognosis, MESH: Predictive Value of Tests, 3. Good health, MESH: Urinary Bladder Neoplasms, [SDV.SP] Life Sciences [q-bio]/Pharmaceutical sciences, Predictive value of tests, Population Surveillance, Female, MESH: Neoplasm Recurrence, Local, Adult, musculoskeletal diseases, medicine.medical_specialty, MESH: Receptor, Fibroblast Growth Factor, Type 3, Urology, Urinary system, MESH: Cystoscopy, MESH: Prognosis, MESH: Population Surveillance, Predictive Value of Tests, Carcinoma, Humans, Receptor, Fibroblast Growth Factor, Type 3, Aged, MESH: Carcinoma, Transitional Cell, Carcinoma, Transitional Cell, Bladder cancer, MESH: Humans, business.industry, MESH: Time Factors, MESH: Adult, medicine.disease, MESH: Male, MESH: Prospective Studies, Surgery, Multicenter study, Urinary Bladder Neoplasms, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Neoplasm Recurrence, Local, business, MESH: Female, Follow-Up Studies
Abstract: Objective To assess the diagnostic and prognostic performance of a noninvasive FGFR3 mutation analysis. After transurethral resection (TUR) of noninvasive bladder transitional cell carcinoma (B-TCC), recurrence occurs in 70% of patients, thus justifying cystoscopic surveillance. Materials and Methods A prospective multicenter study was carried out with a 2-year follow-up of patients with superficial B-TCC. Urine samples were collected before TUR and then before each cystoscopy during follow-up. Screening for the most prevalent FGFR3 mutations was done using urinary cells. The prognostic significance of an FGFR3 mutation at the time of the initial diagnosis was determined. The performance of the test in diagnosing and/or predicting recurrence during follow-up was assessed by calculating sensitivity and specificity. Results Of 191 patients studied, 74 (39%) had a positive analysis before TUR ( FGFR3 mutation group). The presence of an FGFR3 mutation at the time of diagnosis was associated with a shorter time to recurrence ( P = .02). During follow-up, 68 patients from the FGFR3 mutation group were evaluated. FGFR3 mutation analysis showed a sensitivity of 0.73 and a specificity of 0.87 when compared with the results of cystoscopy. A positive urine test was predictive of recurrence either at the time of the positive result or later during the 2-year follow-up, with a sensitivity of 0.70 and a specificity of 0.87. Conclusion Among patients with an FGFR3 mutation in the initial tumor, a noninvasive urine test during follow-up can be valuable in diagnosing or predicting subsequent recurrence.
Published: 2015
Full Text: View/download PDF

31. Predictive factors of recurrence and survival of upper tract urothelial carcinomas

Author: Vitaly Margulis, Jay D. Raman, Thomas F. Chromecki, Morgan Rouprêt, Mesut Remzi, Douglas S. Scherr, Shahrokh F. Shariat, Gregory Verhoest, Karim Bensalah, Christian Seitz, Giacomo Novara, Service d'urologie [Rennes] = Urology [Rennes], Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Department of Urology, Cornell University Medical College, Division of Medical Oncology, Penn State College of Medicine, Penn State System-Pennsylvania Commonwealth System of Higher Education (PCSHE)-Penn State System-Pennsylvania Commonwealth System of Higher Education (PCSHE), Medical University Graz, University of Texas Southwestern Medical Center [Dallas]- The University of Texas Health Science Center at Houston (UTHealth), Department of Oncological and Surgical Sciences, Universita degli Studi di Padova, Hospital Barmherzige Brüder, Hospital Weinviertel-Korneuburg-Landesklinikum Korneuburg, Service d'Urologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Pennsylvania Commonwealth System of Higher Education (PCSHE)-Penn State System-Pennsylvania Commonwealth System of Higher Education (PCSHE)-Penn State System, Università degli Studi di Padova = University of Padua (Unipd), De Villemeur, Hervé, Service d'urologie [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Service d'urologie et transplantation rénales [CHU Pitié-Salpêtrière], and Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Subjects: MESH: Carcinoma, Male, Oncology, predictive factors, Lymphovascular invasion, 030232 urology & nephrology, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, 0302 clinical medicine, nephro-ureterectomy, Stage (cooking), Lymph node, urothelial carcinoma, MESH: Urologic Surgical Procedures, MESH: Urologic Neoplasms, Standard treatment, Prognosis, MESH: Predictive Value of Tests, 3. Good health, Survival Rate, medicine.anatomical_structure, upper tract, 030220 oncology & carcinogenesis, Predictive value of tests, Urologic Surgical Procedures, Female, MESH: Neoplasm Recurrence, Local, Urologic Neoplasms, medicine.medical_specialty, recurrence, MESH: Survival Rate, Urology, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Prognosis, Article, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, Predictive Value of Tests, Internal medicine, medicine, Carcinoma, Humans, Clinical significance, Survival rate, MESH: Humans, business.industry, MESH: Urothelium, medicine.disease, [SDV.MHEP.UN] Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, MESH: Male, transitional carcinoma, Neoplasm Recurrence, Local, Urothelium, business, MESH: Female
Abstract: International audience; OBJECTIVE: UTUCC is a rare tumor, and most reports on prognostic factors come from small single-center series. The objective of this article was to provide an updated overview of current clinical, pathological and biological prognostic factors of UTUC. METHODS: PubMed was searched for records from 2002 to 2010 using the terms "prognostic factors", "recurrence", "survival", and "upper tract urothelial carcinoma". Among identified citations, papers were selected based on their clinical relevance. RESULTS: Classical clinical factors that influence UTUC prognosis include age, presence of symptoms, hydronephrosis, and interval from diagnosis. Many biomarkers have shown promises to better appraise the natural course of UTUC although none is currently used in clinical practice. Stage, grade, lymph node metastases, lymphovascular invasion, tumor necrosis, and tumor architecture are strong pathological parameters. RNU is the standard treatment of localized UTUC. Both laparoscopic and open approaches seem to offer similar cancer control. Lymph node dissection increases staging accuracy and might confer a survival benefit. CONCLUSION: RNU is the standard treatment for most patients with UTUC. Recent multicenter studies confirmed the prognostic value of classical prognostic parameters. Better survival prediction might be obtained with prognostic systems including clinical data and new biomarkers.
Published: 2011
Full Text: View/download PDF

32. Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group

Author: Poortmans , Philip, Bossi , Alberto, Vandeputte , Katia, Bosset , Mathieu, Miralbell , Raymond, Maingon , Philippe, Boehmer , Dirk, Budiharto , Tom, Symon , Zvi, Van Den Bergh , Alfons C M, Scrase , Christopher, Van Poppel , Hendrik, Bolla , Michel, Renseigné , Non, Radiotherapy, Bernard Verbeeten Institute for Radiotherapy, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ) -Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc ( CRLCC - CGFL ), Katholieke Universiteit Leuven ( KU Leuven ), Département de cancérologie et radiothérapie, CHU Grenoble, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER, Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), and Guided Treatment in Optimal Selected Cancer Patients (GUTS)
Subjects: Male, Oncology, PELVIC LYMPHADENECTOMY, medicine.medical_treatment, Planning target volume, THERAPY, DISEASE, 030218 nuclear medicine & medical imaging, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, Imaging, Prostate cancer, 0302 clinical medicine, MESH: Postoperative Period, Postoperative Period, guidelines, ADJUVANT RADIOTHERAPY, MESH : Neoplasm Recurrence, Local, Prostatectomy, MESH: Guidelines as Topic, RADICAL PROSTATECTOMY, Hematology, prostate cancer, 3. Good health, 030220 oncology & carcinogenesis, MESH: Neoplasm Recurrence, Local, MESH : Prostatic Neoplasms, medicine.medical_specialty, MESH : Prostatectomy, MESH : Male, Guidelines as Topic, [SDV.CAN]Life Sciences [q-bio]/Cancer, LOCAL RECURRENCE, organ at risk definition, 03 medical and health sciences, MESH: Prostatectomy, Internal medicine, Radiation oncology, medicine, Humans, EXTRACAPSULAR EXTENSION, Radiology, Nuclear Medicine and imaging, Medical physics, MESH : Guidelines as Topic, MESH : Postoperative Period, MESH: Humans, prostatectomy, business.industry, MESH : Humans, Prostatic Neoplasms, Cancer, BLADDER, medicine.disease, MESH: Male, Post operative radiotherapy, Radiation therapy, EMISSION-TOMOGRAPHY, HIGH-RISK, Prostate Bed, MESH: Prostatic Neoplasms, target definition, Neoplasm Recurrence, Local, business
Abstract: The appropriate application of 3-D conformal radiotherapy, intensity modulated radiotherapy or image guided radiotherapy for patients undergoing post-operative radiotherapy for prostate cancer requires a standardisation of the target volume definition and delineation as well as stanclardisation of the clinical quality assurance procedures. Recommendations for this are presented on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) Radiation Oncology Group and in addition to the already published guidelines for radiotherapy as the primary treatment. (c) 2007 Elsevier Ireland Ltd. All rights reserved.
Published: 2007
Full Text: View/download PDF

33. Ten-year survival and risk of relapse for testicular cancer

Author: Tiiu Aareleid, Jean-Michel Lutz, G. Hedelin, Giovanna Tagliabue, Ivan Plesko I, Milena Sant, Renée Otter, David Forman, Maria Elisa Artioli, Jan Willem Coebergh, Marc Colonna, Maja Žakelj Primic, Jadwiga Rachtan, Franco Berrino, N. Raverdy, Department of Preventive and Predictive Medicine, Unit of Etiological Epidemiology and Prevention, Istituto Nazionale per lo Studio e la Cura dei Tumori, Department of Epidemiology and Biostatistics, National Institute for Health Development and Estonian Cancer Registry, Modena Cancer Registry, Università degli Studi di Modena e Reggio Emilia (UNIMORE), Eindhoven Cancer Registry, Registre des Cancers de l'Isère, registre des Cancers de l'Isère, Northern and Yorkshire Cancer Registry and Information Service, Registre des cancers du Bas-Rhin, CRLCC Paul Strauss, Cracow Cancer Registry, M.Sklodowsk-Curie Memorial Cancer Institute, Registre Genevois des Tumeurs, CHU Genève, Integraal Kankercentrum Noord, Registre général des cancers de la Somme, CHU Amiens-Picardie, National Cancer Registry of Slovakia and Department of Cancer Epidemiology, Cancer Research Institute of Slovak Academy of Sciences, Cancer Registry of Slovenia, Institute of Oncology, Varese Cancer Registry, Vesin, Aurélien, and Università degli Studi di Modena e Reggio Emilia = University of Modena and Reggio Emilia (UNIMORE)
Subjects: Male, Cancer Research, endocrine system diseases, MESH: Registries, 030232 urology & nephrology, urologic and male genital diseases, DISEASE, 0302 clinical medicine, Risk Factors, MESH: Risk Factors, Epidemiology, Registries, MESH: Testicular Neoplasms, MESH: Aged, education.field_of_study, MESH: Middle Aged, TESTIS, Hazard ratio, Middle Aged, GERM-CELL TUMORS, CHEMOTHERAPY, 3. Good health, Seminoma, testicular cancer, Europe, Oncology, 030220 oncology & carcinogenesis, MESH: Survival Analysis, population cancer registries, MESH: Neoplasm Recurrence, Local, Adult, medicine.medical_specialty, Population, survival, 03 medical and health sciences, Testicular Neoplasms, Internal medicine, medicine, MANAGEMENT, Humans, Risk factor, education, Testicular cancer, Survival analysis, Aged, MESH: Humans, business.industry, MORTALITY, Cancer, MESH: Adult, medicine.disease, Survival Analysis, stage, TRENDS, MESH: Male, Surgery, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Seminoma, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Europe, Neoplasm Recurrence, Local, business, EUROPEAN COUNTRIES
Abstract: Effective treatments for testicular cancer have been available since the 1970s, yet EURO-CARE uncovered marked inter-country survival differences for this disease. To investigate these differences, we reviewed clinical records of 1350 testicular cancer cases diagnosed during 1987-1992 from 13 population-based cancer registries in nine European countries. Patients were followed up for life status and relapse. Ten-year observed survival was estimated by the Kaplan-Meier method. Cox multivariable analyses were performed separately for seminomas and non-seminomas. Overall, 66% of seminomas and 36% of non-seminomas were limited to the testis. Ten-year survival was 63% (Estonia) to 94% (Switzerland, Slovenia) for seminoma; 47% (Estonia) to 90% (Yorkshire, UK, The Netherlands) for non-seminoma. Multivariable analysis adjusted for country, age and stage showed that hazard ratios (HRs) of death differed little between western European registries, and were mainly attributable to differing stage at diagnosis. Significantly higher than reference HRs in Estonia and Poland suggest inadequacy or unavailability of treatments. (c) 2006 Elsevier Ltd. All rights reserved.
Published: 2007
Full Text: View/download PDF

34. A case–control study of patients with squamous cell carcinoma of the oral cavity and oropharynx treated with pulsed-dose-rate brachytherapy

Author: Alain Haddad, Valentin Harter, Pierre Graff, Didier Peiffert, Michel Lapeyre, I. Buchheit, Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), UNICANCER, Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université Paris Descartes - Paris 5 (UPD5)-Université de Lorraine (UL), and Institut de Cancérologie de Lorraine - Alexis Vautrin (ICL)
Subjects: Male, medicine.medical_treatment, Brachytherapy, Oral cavity, 030218 nuclear medicine & medical imaging, MESH: Mouth Neoplasms, MESH: Clinical Protocols, 0302 clinical medicine, MESH: Aged, 80 and over, Clinical Protocols, MESH: Dose Fractionation, MESH: Radiotherapy Dosage, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, Radiotherapy Dosage, MESH: Carcinoma, Squamous Cell, Middle Aged, MESH: Case-Control Studies, 3. Good health, Oropharyngeal Neoplasms, Oncology, Head and Neck Neoplasms, 030220 oncology & carcinogenesis, Carcinoma, Squamous Cell, Female, Mouth Neoplasms, MESH: Brachytherapy, MESH: Neoplasm Recurrence, Local, Adult, medicine.medical_specialty, Urology, 03 medical and health sciences, Head and neck, PDR, medicine, Humans, Radiology, Nuclear Medicine and imaging, Pulsed-Dose Rate Brachytherapy, Basal cell, In patient, Aged, MESH: Humans, business.industry, Squamous Cell Carcinoma of Head and Neck, Case-control study, MESH: Adult, medicine.disease, Head and neck squamous-cell carcinoma, MESH: Male, Surgery, MESH: Head and Neck Neoplasms, MESH: Oropharyngeal Neoplasms, Case-Control Studies, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Dose Fractionation, Radiation, Neoplasm Recurrence, Local, Dose rate, business, MESH: Female
Abstract: International audience; PURPOSE:Pulsed-dose-rate (PDR) brachytherapy is thought to mimic the radiobiological benefits of continuous low-dose-rate (cLDR) delivery but is safer for medical personnel. We set out to evaluate the outcomes of this technique in patients with head and neck squamous cell carcinoma.METHODS AND MATERIALS:A total of 36 consecutive patients treated with PDR brachytherapy were randomly matched to 72 cLDR controls according to T-stage, tumor site, and management strategy. Local recurrence and late complications were compared between the two groups.RESULTS:Baseline characteristics were similar in both groups. Oral cavity cancers predominated at 81%, and 89% had T1/T2 tumors. Seventy-five percent of patients underwent surgery before radiation treatment. Median followup was 59 and 30 months for cLDR and PDR patients, respectively. Three-year actuarial local recurrence-free survival was 97% and 94% for cLDR and PDR patients, respectively (p = 0.77). Three-year cumulative risk of Grade ≥2 complications was 45% and 32% for cLDR and PDR patients, respectively (p = 0.2). For cLDR, a dose rate exceeding 68 cGy/h resulted in more complications (RR 5.3, p < 0.05). Similarly, PDR patients receiving ≥75 cGy/pulse were at higher risk.CONCLUSIONS:PDR brachytherapy in head and neck squamous cell carcinoma yields comparable results to cLDR treatment. Dose rate was correlated with the risk of late complications, regardless of technique.
Published: 2014
Full Text: View/download PDF

35. Autophagy Controls BCG-Induced Trained Immunity and the Response to Intravesical BCG Therapy for Bladder Cancer

Author: Esther van de Vosse, Vinod Kumar, Reinout van Crevel, Marije Oosting, Mihai G. Netea, Aylwin Ng, Lambertus A. Kiemeney, Egbert Oosterwijk, Cisca Wijmenga, Georgios Chamilos, Jessica Quintin, Frank L. van de Veerdonk, Johanneke Kleinnijenhuis, Jos W. M. van der Meer, Anne J. Grotenhuis, Ramnik J. Xavier, Kathrin Buffen, Leo A. B. Joosten, Sita H. Vermeulen, Radboud University Medical Center [Nijmegen], Massachusetts General Hospital [Boston], University Medical Center Groningen [Groningen] (UMCG), Leiden University Medical Center (LUMC), University of Crete [Heraklion] (UOC), Massachusetts Institute of Technology (MIT), Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI), and Department of Health and Life Sciences
Subjects: MESH: Vesicular Transport Proteins, medicine.medical_treatment, lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4], Vesicular Transport Proteins, MESH: Adjuvants, Immunologic, MESH: Monocytes, Cancer immunotherapy, Animal Cells, lcsh:QH301-705.5, WEST-AFRICA, Innate Immune System, MESH: Cytokines, MESH: Polymorphism, Single Nucleotide, 3. Good health, Vaccination, MESH: BCG Vaccine, Administration, Intravesical, Oncology, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], Cytokines, CHILD SURVIVAL, VACCINATION, Cellular Types, Immune Cells, Immunology, Antineoplastic Agents, Microbiology, Immune Activation, HOST-DEFENSE, Adjuvants, Immunologic, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], Genetics, Humans, MESH: Autophagy, Molecular Biology, MESH: Kaplan-Meier Estimate, Blood Cells, MESH: Humans, Interleukins, Immunity, Biology and Life Sciences, Immunotherapy, Molecular Development, MESH: Autophagy-Related Protein 5, RANDOMIZED-TRIAL, Genitourinary Tract Tumors, MESH: Microtubule-Associated Proteins, Urinary Bladder Neoplasms, MESH: Antineoplastic Agents, Parasitology, lcsh:RC581-607, BCG vaccine, Developmental Biology, MESH: Mycobacterium bovis, beta-Glucans, [SDV]Life Sciences [q-bio], Cancer Treatment, Autophagy-Related Proteins, Kaplan-Meier Estimate, [SDV.IMM.II]Life Sciences [q-bio]/Immunology/Innate immunity, Autophagy-Related Protein 5, MESH: Autophagy-Related Proteins, White Blood Cells, NATURAL-KILLER-CELLS, Medicine and Health Sciences, Vaccines, MESH: beta-Glucans, Infectious Disease Immunology, Vaccination and Immunization, Bladder Cancer, Mycobacterium bovis, MESH: Urinary Bladder Neoplasms, MONOCYTES, BCG Vaccine, [SDV.IMM]Life Sciences [q-bio]/Immunology, Microtubule-Associated Proteins, MESH: Neoplasm Recurrence, Local, Research Article, lcsh:Immunologic diseases. Allergy, Attenuated Vaccines, Urology, ATG5, Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9], Polymorphism, Single Nucleotide, complex mixtures, DENDRITIC CELLS, Cancer Immunotherapy, Immunomodulation, Immune system, Virology, medicine, Autophagy, IMMUNOTHERAPY, MESH: Administration, Intravesical, CANDIDA-ALBICANS, business.industry, Cancers and Neoplasms, Cell Biology, MESH: Vaccination, lcsh:Biology (General), Immune System, Inflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5], Clinical Immunology, Neoplasm Recurrence, Local, business
Abstract: The anti-tuberculosis-vaccine Bacillus Calmette-Guérin (BCG) is the most widely used vaccine in the world. In addition to its effects against tuberculosis, BCG vaccination also induces non-specific beneficial effects against certain forms of malignancy and against infections with unrelated pathogens. It has been recently proposed that the non-specific effects of BCG are mediated through epigenetic reprogramming of monocytes, a process called trained immunity. In the present study we demonstrate that autophagy contributes to trained immunity induced by BCG. Pharmacologic inhibition of autophagy blocked trained immunity induced in vitro by stimuli such as β–glucans or BCG. Single nucleotide polymorphisms (SNPs) in the autophagy genes ATG2B (rs3759601) and ATG5 (rs2245214) influenced both the in vitro and in vivo training effect of BCG upon restimulation with unrelated bacterial or fungal stimuli. Furthermore, pharmacologic or genetic inhibition of autophagy blocked epigenetic reprogramming of monocytes at the level of H3K4 trimethylation. Finally, we demonstrate that rs3759601 in ATG2B correlates with progression and recurrence of bladder cancer after BCG intravesical instillation therapy. These findings identify a key role of autophagy for the nonspecific protective effects of BCG., Author Summary Next to its effects against tuberculosis, BCG vaccination also induces non-specific beneficial effects on immune cells to increase their ability to control unrelated pathogens. It has been recently proposed that the non-specific effects of BCG are mediated through epigenetic reprogramming of monocytes, a process called trained immunity. Little is known regarding the intracellular events controlling its induction. In this study we identified autophagy as a key player in trained immunity. Pharmacological inhibition of autophagy as well as polymorphisms in autophagy-related genes blocked BCG-induced trained immunity. Furthermore, BCG vaccine is also used to treat bladder cancer. Genetic polymorphisms in autophagy-related genes correlated with progression and recurrence of bladder cancer after treatment with BCG therapy. These findings open new possibilities for improvement of future BCG-based vaccines to be used against infections and malignancies.
Published: 2014
Full Text: View/download PDF

36. Impact of dosimetric parameters on local control for patients treated with three-dimensional pulsed dose-rate brachytherapy for cervical cancer

Author: Claude Krzisch, Didier Peiffert, Sabrina Boyrie, Valentin Harter, Martine Delannes, Xavier Montbarbon, Claire Charra-Brunaud, Isabelle Barillot, Anne Ducassou, Philippe Lang, Marie-Hélène Baron, Youlia M. Kirova, Institut Claudius Regaud, Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), UNICANCER, Département de radiothérapie oncologique [Paris], Institut Curie [Paris], Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), CHU Amiens-Picardie, Service d'Oncologie Radiothérapie [CHU Pitié Salpétrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de Radiothérapie [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Léon Bérard [Lyon], Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université Paris Descartes - Paris 5 (UPD5)-Université de Lorraine (UL), CRLCC Institut Claudius Regaud, Institut de Cancérologie de Lorraine - Alexis Vautrin (ICL), Institut Curie, Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc (CRLCC - CGFL), Hôpital Universitaire d'Amiens, Service de Radiothérapie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Service de radiothérapie (CHRU Besançon), and Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)
Subjects: medicine.medical_treatment, Brachytherapy, Planning target volume, Uterine Cervical Neoplasms, MESH: Magnetic Resonance Imaging, MESH: Aged, 80 and over, Risk Factors, MESH: Risk Factors, Prospective Studies, Prospective cohort study, MESH: Radiotherapy Dosage, MESH: Treatment Outcome, Cervical cancer, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, medicine.diagnostic_test, Radiotherapy Dosage, MESH: Carcinoma, Squamous Cell, MESH: Follow-Up Studies, Middle Aged, Magnetic Resonance Imaging, 3. Good health, MESH: Uterine Cervical Neoplasms, Treatment Outcome, Oncology, MESH: Survival Analysis, Carcinoma, Squamous Cell, Female, MESH: Tomography, X-Ray Computed, MESH: Brachytherapy, MESH: Neoplasm Recurrence, Local, Adult, MESH: Imaging, Three-Dimensional, Adenocarcinoma, Kerma, Imaging, Three-Dimensional, MESH: Dose-Response Relationship, Radiation, medicine, Humans, Radiology, Nuclear Medicine and imaging, Pulsed-Dose Rate Brachytherapy, External beam radiotherapy, Aged, Pulsed dose-rate brachytherapy, MESH: Humans, business.industry, MESH: Adenocarcinoma, Magnetic resonance imaging, Dose-Response Relationship, Radiation, MESH: Adult, medicine.disease, Survival Analysis, MESH: Prospective Studies, Three-dimensional brachytherapy, Local control, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Neoplasm Recurrence, Local, business, Nuclear medicine, Tomography, X-Ray Computed, MESH: Female, Follow-Up Studies
Abstract: International audience; To investigate the impact of dose-volume histograms parameters on local control of three-dimensional (3D) image-based pulsed dose-rate brachytherapy (BT).METHODS AND MATERIALS:Within a French multicentric prospective study, the data of the 110 patients treated for cervical cancer with external beam radiotherapy followed by 3D image-based and optimized pulsed dose-rate BT were analyzed. Delineation procedures were performed on magnetic resonance imaging in a minority of cases and on CT for the majority of cases, adapted from the Gynaecological Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology recommendations. Optimization procedure was left to the discretion of the treating center.RESULTS:At 2 years, local control rate reached 78%. Dose to Point A, total reference air kerma, and intermediate-risk clinical target volume (IR-CTV) V60 were predictive factors for local control (p = 0.001, p = 0.001, and p = 0.013, respectively). Patients with IR-CTV V60
Published: 2014
Full Text: View/download PDF

37. Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial†

Author: L. Miglianico, D. Azria, E. Paris, Patrick Ezra, C. Lemanski, Beata Juzyna, Katty Malekzadeh, Anne Delarochefordiere, Emmanuel Rio, J.P. Pignon, Eric Deutsch, Isabelle Martel-Lafay, T. Conroy, Yves Becouarn, David Malka, Antonin Levy, Institut Gustave Roussy (IGR), CRLCC Val d'Aurelle - Paul Lamarque, Institut Curie [Paris], Centre Léon Bérard [Lyon], Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER, Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université Paris Descartes - Paris 5 (UPD5)-Université de Lorraine (UL), Centre Hospitalier Privé Saint-Grégoire, Institut Bergonié [Bordeaux], UNICANCER [Paris], Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Institut Curie, Institut de cancérologie de l'Ouest - Paul Papin (ICO - Paul Papin), Institut de Cancérologie de Lorraine - Alexis Vautrin (ICL), and Institut Bergonié - CRLCC Bordeaux
Subjects: Male, MESH: Radiotherapy, Phases of clinical research, Gastroenterology, chemoradiotherapy, MESH: Anus Neoplasms, 0302 clinical medicine, MESH: Cetuximab, cetuximab, Medicine, MESH: Chemoradiotherapy, MESH: Aged, 0303 health sciences, education.field_of_study, MESH: Middle Aged, Cetuximab, Hematology, Middle Aged, phase II, Anus Neoplasms, targeted therapy, MESH: Drug-Related Side Effects and Adverse Reactions, 3. Good health, Oncology, Fluorouracil, 030220 oncology & carcinogenesis, Female, MESH: Neoplasm Recurrence, Local, medicine.drug, Adult, medicine.medical_specialty, Drug-Related Side Effects and Adverse Reactions, anal cancer, Population, Antibodies, Monoclonal, Humanized, Loading dose, Disease-Free Survival, 03 medical and health sciences, Internal medicine, Anal cancer, Humans, education, Adverse effect, 030304 developmental biology, Aged, MESH: Humans, Radiotherapy, business.industry, toxicity, MESH: Adult, medicine.disease, MESH: Male, Surgery, MESH: Cisplatin, MESH: Antibodies, Monoclonal, Humanized, MESH: Disease-Free Survival, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Cisplatin, Neoplasm Recurrence, Local, business, MESH: Fluorouracil, MESH: Female, Chemoradiotherapy
Abstract: Background The ACCORD 16 phase II trial aimed to evaluate the objective response rate after combination of conventional chemoradiotherapy (CRT) and cetuximab in locally advanced anal canal carcinoma (LAACC). Patients and methods Immunocompetent patients with histologically confirmed LAACC received CRT [45 gray (Gy)] in 25 fractions over 5 weeks, fluorouracil and cisplatin during weeks 1 and 5), in combination with weekly dose of cetuximab (250 mg/m2 with a loading dose of 400 mg/m2 1 week before irradiation), and a standard dose boost (20 Gy). The trial was originally designed to include 81 patients to detect a 15% of objective response increase with the new combination in comparison with CRT. Results The trial was prematurely stopped after the declaration of 15 serious adverse events (SAEs) in 14 out of 16 patients. Five patients received the entire planned treatment, and the compliance was higher after amendments of the protocol. Among the 15 SAEs, 6 were unexpected. Grade (G) 3/4 acute toxic effects, observed in 88% patients, were general (n = 13, 81%), digestive (n = 9, 56%), dermatological (n = 5, 31%), infectious (n = 4, 25%), haematological (n = 3, 19%), and others (n = 9); and three patients suffered from six G3/4 late toxic effects. No treatment-related death was reported. All 11 assessable patients had an objective response consisting of six complete (55%) and five partial (45%) response 2 months after the end of the treatment. Thirteen patients were followed up with a median of 22 months [95% confidence interval (CI ): 18–27] and had a 1-year colostomy-free survival, progression-free and overall survival rate of 67% (95% CI: 40%–86%), 62% (95% CI: 36%–82%), and 92% (95% CI: 67%–99%), respectively. Conclusion CRT plus cetuximab was unacceptably toxic in this population of patients. Results of others phase II trials evaluating this combination are awaited to confirm these findings. Eudra CT No 2007-007029-38.
Published: 2013
Full Text: View/download PDF

38. VEGFR1 and NRP1 endothelial expressions predict distant relapse after radical prostatectomy in clinically localized prostate cancer

Author: Matthieu, Talagas, Arnaud, Uguen, Ronan, Garlantezec, Georges, Fournier, Laurent, Doucet, Eric, Gobin, Pascale, Marcorelles, Alain, Volant, Marc, DE Braekeleer, CHRU Brest - Laboratoire d'Anatomo-Pathologie (CHU - AnaPath), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Département de santé publique [Brest], Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Hôpital Augustin Morvan, Génétique, génomique fonctionnelle et biotechnologies (UMR 1078) (GGB), Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO)-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), Le Corre, Morgane, Hôpital Augustin Morvan-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), EFS-Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), and Université de Brest (UBO)
Subjects: Male, animal structures, MESH: Lymphatic Metastasis, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Neuropilin-1, MESH: Prognosis, Immunoenzyme Techniques, angiogenesis, MESH: Prostatectomy, [SDV.CAN] Life Sciences [q-bio]/Cancer, Humans, NRP1, MESH: Immunoenzyme Techniques, Aged, Neoplasm Staging, Retrospective Studies, MESH: Aged, Vascular Endothelial Growth Factor Receptor-1, Prostate cancer, MESH: Vascular Endothelial Growth Factor Receptor-1, MESH: Humans, MESH: Middle Aged, prostatectomy, MESH: Vascular Endothelial Growth Factor Receptor-2, Prostatic Neoplasms, MESH: Retrospective Studies, tissue array analysis, MESH: Neoplasm Staging, MESH: Follow-Up Studies, Middle Aged, respiratory system, Prognosis, Vascular Endothelial Growth Factor Receptor-2, MESH: Case-Control Studies, Neuropilin-1, MESH: Male, VEGFR1, Case-Control Studies, Lymphatic Metastasis, MESH: Prostatic Neoplasms, immunohistochemistry, cardiovascular system, Endothelium, Vascular, MESH: Endothelium, Vascular, Neoplasm Recurrence, Local, MESH: Tissue Array Analysis, MESH: Neoplasm Recurrence, Local, Follow-Up Studies
Abstract: International audience; Prostate cancer can usually be treated at a clinically localized stage by radical prostatectomy. Unfortunately, within 10 years following surgery, 30% of patients experience local or distant relapse. Few data exist on the association of markers of angiogenesis and distant relapse after radical prostatectomy. By immunohistochemistry in tissue microarray, we compared the expression pattern of hypoxia inducible factor 1, alpha subunit (HIF1α) and vascular endothelial growth factor (VEGF) and its receptors in 45 patients with distant relapse and 68 patients without relapse after radical prostatectomy. Expressions of HIF1α and VEGF were assessed in prostate tumor cells and those of VEGFR1, VEGFR2 and neuropilin 1 in tumor and endothelial cells. The five molecules studied were expressed by all tumors, with the exception of neuropilin 1 in endothelial cells for one tumor. Strong endothelial expression of VEGFR1 appeared to be an independent predictor of distant relapse. A moderate to strong endothelial expression of neuropilin 1 was in turn an independent predictor of absence of distant relapse. No significant difference was found for HIF1α, VEGF, VEGFR1, VEGFR2 and neuropilin 1 expression in tumor cells, nor for VEGFR2 in endothelial cells, between the two groups. To our knowledge, this is the first study to evaluate the prognostic value of VEGFR1, VEGFR2 and neuropilin 1 in endothelial cells in prostate cancer after radical prostatectomy. The evaluation by immunohistochemistry of endothelial expression of neuropilin 1 and VEGFR1 could be an additional tool in the assessment of tumor aggressiveness of clinically localized prostate cancer to better identify patients at high risk of distant relapse.
Published: 2013

39. Treatment of recurrent intrahepatic cholangiocarcinoma

Author: Marc Pracht, Karim Boudjema, Laurent Sulpice, Eveline Boucher, Michel Rayar, Bernard Meunier, Foie, métabolismes et cancer, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Service de Chirurgie Hépatobiliaire et Digestive [Rennes] = Hepatobiliary and Digestive Surgery [Rennes], CHU Pontchaillou [Rennes], CRLCC Eugène Marquis (CRLCC), Le Corre, Morgane, Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
Subjects: Male, medicine.medical_treatment, Perineural invasion, Kaplan-Meier Estimate, 030230 surgery, MESH: Risk Assessment, Gastroenterology, Cholangiocarcinoma, 0302 clinical medicine, Risk Factors, MESH: Risk Factors, MESH: Liver Neoplasms, Medicine, Lymph node, Intrahepatic Cholangiocarcinoma, MESH: Aged, Liver Neoplasms, Recurrent Intrahepatic Cholangiocarcinoma, 3. Good health, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Female, MESH: Neoplasm Recurrence, Local, medicine.medical_specialty, Risk Assessment, MESH: Bile Duct Neoplasms, 03 medical and health sciences, Internal medicine, Humans, Survival rate, MESH: Kaplan-Meier Estimate, Aged, Retrospective Studies, MESH: Humans, business.industry, MESH: Retrospective Studies, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Odds ratio, MESH: Cholangiocarcinoma, MESH: Male, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Surgery, Radiation therapy, Bile Ducts, Intrahepatic, MESH: Bile Ducts, Intrahepatic, Bile Duct Neoplasms, Hepatectomy, Neoplasm Recurrence, Local, business, MESH: Female
Abstract: Background The aims of this study were to evaluate risk factors for recurrence following hepatectomy with curative intent for intrahepatic cholangiocarcinoma (ICC), and predictors of survival after intrahepatic recurrence. Methods All patients with ICC who underwent liver resection between January 1997 and August 2011 in a single centre were analysed retrospectively. Clinicopathological factors likely to influence recurrence and postrecurrence survival were assessed by univariable and multivariable analysis. Results A total of 87 patients were analysed. R0 resection was achieved in 65 patients (75 per cent). Eighty-three patients survived more than 1 month after resection. Median survival was 33 months, with 1-, 3- and 5-year actuarial survival rates of 79, 47 and 31 per cent respectively. Recurrence occurred in 45 (54 per cent) of the 83 patients, most frequently in the liver (25 patients). Satellite nodules (odds ratio (OR) 8·17, 95 per cent confidence interval 1·38 to 48·53; P = 0·021), hilar lymph node metastases (OR 5·24, 1·07 to 25·75; P = 0·041) and perineural invasion (OR 9·68, 1·07 to 87·54; P = 0·043) were identified as independent risk factors for recurrence. Repeat hepatectomy (P = 0·003) and intra-arterial yttrium-90 radiotherapy (P = 0·048) were associated with longer survival after intrahepatic recurrence. Conclusion Satellite nodules, hilar lymph node metastases and perineural invasion are risk factors for recurrence following resection with curative intent for ICC. Repeat hepatectomy and labelled yttrium-90 radiotherapy may improve survival after intrahepatic recurrence.
Published: 2012
Full Text: View/download PDF

40. Risk of cancer-specific mortality following recurrence after radical nephroureterectomy

Author: Jay D. Raman, Richard Zigeuner, Jens Hansen, Shahrokh F. Shariat, Wassim Kassouf, Mesut Remzi, Andrew J. Vickers, Armin Pycha, Yair Lotan, Juan Ignacio Martínez-Salamanca, Felix K.-H. Chun, Karim Bensalah, Eugene K. Cha, Christian Seitz, Evanguelos Xylinas, Evi Comploj, Pierre I. Karakiewicz, Douglas S. Scherr, Surena F. Matin, Daniel Sjöberg, Michael Rink, Eiji Kikuchi, Vitaly Margulis, Giacomo Novara, Richard K. Lee, Weill Medical College of Cornell University [New York], Department of Experimental Pharmacology and Toxicology, Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg] (UKE)-Cardiovascular Research Center, General Hospital of Bolzano, Health Robotics S.r.l., Department of Urology, University of Texas Southwestern Medical Center [Dallas]- The University of Texas Health Science Center at Houston (UTHealth), Cancer Prognostics and Health Outcomes Unit, Université de Montréal (UdeM), Hospital Weinviertel-Korneuburg-Landesklinikum Korneuburg, Service d'urologie [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Keio University School of Medicine [Tokyo, Japan], Medical University Graz, This study was conducted for the Upper Tract Urothelial Carcinoma Collaboration (UTUCC)., Service d'urologie [Rennes] = Urology [Rennes], and Hôpital Pontchaillou-CHU Pontchaillou [Rennes]
Subjects: Male, 030232 urology & nephrology, Disease, Nephrectomy, Cohort Studies, 0302 clinical medicine, Risk Factors, Surgical oncology, MESH: Risk Factors, Medicine, MESH: Ureteral Neoplasms, Cancer specific mortality, MESH: Cohort Studies, Urothelial carcinoma, MESH: Aged, MESH: Middle Aged, MESH: Follow-Up Studies, MESH: Neoplasm Staging, Middle Aged, Prognosis, 3. Good health, Survival Rate, Natural history, Oncology, 030220 oncology & carcinogenesis, Female, [SDV.IB]Life Sciences [q-bio]/Bioengineering, MESH: Neoplasm Recurrence, Local, Cohort study, medicine.medical_specialty, MESH: Survival Rate, Urology, [SDV.CAN]Life Sciences [q-bio]/Cancer, Article, MESH: Prognosis, 03 medical and health sciences, Humans, Survival rate, Aged, Neoplasm Staging, MESH: Humans, Ureteral Neoplasms, business.industry, MESH: Lymph Node Excision, MESH: Male, MESH: Nephrectomy, Upper tract, Lymph Node Excision, Surgery, Neoplasm Recurrence, Local, business, MESH: Female, Follow-Up Studies
Abstract: International audience; PURPOSE: To describe the natural history and identify predictors of cancer-specific survival in patients who experience disease recurrence after radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC). METHODS: Of 2,494 UTUC patients treated with RNU without neoadjuvant chemotherapy, 597 patients experienced disease recurrence. A total of 148 patients (25 %) received adjuvant chemotherapy before disease recurrence. Multivariable Cox regression model addressed time to cancer-specific mortality after disease recurrence. RESULTS: The median time from RNU to disease recurrence was 12 months (interquartile range 5-22). A total of 491 (82 %) of 597 patients died from UTUC, and 8 patients (1.3 %) died from other causes. The median time from disease recurrence to death of UTUC was 10 months. Actuarial cancer-specific survival estimate at 12 months after disease recurrence was 35 %. On multivariable analysis that adjusted for the effects of standard clinicopathologic characteristics, higher tumor stages [hazard ratio (HR) pT3 vs. pT0-T1: 1.66, p = 0.001; HR pT4 vs. pT0-T1: 1.90, p = 0.002], absence of lymph node dissection (HR 1.28, p = 0.041), ureteral tumor location (HR 1.44, p < 0.0005) and a shorter interval from surgery to disease recurrence (p < 0.0005) were significantly associated with cancer-specific mortality. The adjusted 6-, 12- and 24-month postrecurrence cancer-specific mortality was 73, 60 and 57 %, respectively. CONCLUSIONS: Approximately 80 % of patients who experience disease recurrence after RNU die within 2 years after recurrence. Patients with non-organ-confined stage, absence of lymph node dissection, ureteral tumor location and/or shorter time to disease recurrence died of their tumor more quickly than their counterparts. These factors should be considered in patient counseling and risk stratification for salvage treatment decision making.
Published: 2012
Full Text: View/download PDF

41. Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up

Author: Gilles Salles, Philippe Colombat, Charles Foussard, Franck Morschhauser, F. Lazreg, Pierre Soubeyran, Corinne Haioun, Vincent Delwail, Nicole Brousse, Catherine Sebban, Pauline Brice, Philippe Solal-Celigny, Hervé Tilly, Catherine Thieblemont, Loïc Bergougnoux, Eric Deconinck, Service d'hématologie [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau, Service d'anatomie pathologique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Service d'Hematologie, Hospices Civils de Lyon (HCL)-Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Service d'hématologie, Hôpital Claude Huriez-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service d'hématologie-oncologie adultes, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Plateforme de génétique moléculaire des cancers d'Aquitaine, Institut Bergonié - CRLCC Bordeaux, Service d'Anatomie et de Cytologie Pathologiques [Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Jean Minjoz, Service d'hématologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel Dieu, Service d'Oncologie Médicale, Centre Léon Bérard [Lyon], Service d'oncologie, CRLCC Henri Becquerel, Service d'Hématologie, Roche, Onco-radiothérapie, hématologie, Centre Jean Bernard, CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Claude Huriez [Lille], CHU Lille-CHU Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Bergonié [Bordeaux], UNICANCER-UNICANCER, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Centre Jean Bernard [Institut Inter-régional de Cancérologie - Le Mans], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Hôpital Bretonneau-CHRU Tours, Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Hospices Civils de Lyon ( HCL ) -Centre Hospitalier Lyon Sud [CHU - HCL] ( CHLS ), Hospices Civils de Lyon ( HCL ), Hôpital Claude Huriez-Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ) -Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Université de Poitiers-Centre hospitalier universitaire de Poitiers ( CHU Poitiers ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -hopital Jean Minjoz, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), CHU Angers-Hôtel Dieu, and Saas, Philippe
Subjects: Male, MESH : Immunization, Passive, MESH : Induction Chemotherapy, Follicular lymphoma, Kaplan-Meier Estimate, Gastroenterology, Antibodies, Monoclonal, Murine-Derived, MESH: Lymphoma, Follicular, 0302 clinical medicine, [ SDV.IMM ] Life Sciences [q-bio]/Immunology, MESH : Female, Lymphoma, Follicular, MESH: Treatment Outcome, education.field_of_study, MESH: Middle Aged, MESH : Neoplasm Recurrence, Local, Induction Chemotherapy, Hematology, MESH: Follow-Up Studies, MESH : Adult, Middle Aged, MESH: Induction Chemotherapy, 3. Good health, MESH : Antineoplastic Agents, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, MESH : Disease-Free Survival, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, Rituximab, MESH: Immunization, Passive, MESH: Neoplasm Recurrence, Local, medicine.drug, Adult, medicine.medical_specialty, [SDV.IMM] Life Sciences [q-bio]/Immunology, MESH : Male, Population, Antineoplastic Agents, MESH : Treatment Outcome, Disease-Free Survival, MESH : Kaplan-Meier Estimate, 03 medical and health sciences, Internal medicine, medicine, Humans, MESH : Middle Aged, Progression-free survival, education, MESH: Kaplan-Meier Estimate, MESH: Humans, business.industry, MESH : Lymphoma, Follicular, MESH : Humans, Immunization, Passive, Induction chemotherapy, MESH : Follow-Up Studies, MESH: Adult, medicine.disease, MESH: Male, MESH : Antibodies, Monoclonal, Murine-Derived, Lymphoma, Surgery, MESH: Antibodies, Monoclonal, Murine-Derived, MESH: Disease-Free Survival, MESH: Antineoplastic Agents, Neoplasm Recurrence, Local, business, Diffuse large B-cell lymphoma, MESH: Female, Progressive disease, Follow-Up Studies, 030215 immunology
Abstract: International audience; BACKGROUND: The purpose of this study was to report long-term results of rituximab induction monotherapy in patients with low-tumor-burden follicular lymphoma (LTBFL). PATIENTS AND METHODS: Of 49 first-line LTBFL patients who received weekly doses of rituximab (375 mg/m(2)), 46 have been followed with a long-term analysis of clinical and molecular responses. RESULTS: Best clinical response (at any staging within a year following treatment) was 80%, 24 (52%) patients had complete or unconfirmed complete response, 13 (28%) had partial response and 9 (20%) had stable or progressive disease. Of 31 patients having a positive bcl2-JH rearrangement, 15 (48%) became negative following treatment. After 83.9 months of follow-up (95% confidence interval 6.4-92.8 months), the median progression-free survival is 23.5 months and overall survival (OS) is 91.7%. Five patients died (one progression, one myelodysplasia, one diffuse large B-cell lymphoma and two solid tumors). Seven patients (15%) are progression-free including five who are bcl2 informative. No unexpected long-term adverse event has been observed. CONCLUSION: A significant proportion of patients remain progression-free 7 years after a single 4-dose rituximab treatment in first-line LTBFL. The 7-year overall survivalOS is very high in this selected population of patients.
Published: 2012
Full Text: View/download PDF

42. Subclassification of pT3 urothelial carcinoma of the renal pelvicalyceal system is associated with recurrence-free and cancer-specific survival: proposal for a revision of the current TNM classification

Author: Kanishka Sircar, Shahrokh F. Shariat, Theresa M. Koppie, Wassim Kassouf, Shuji Mikami, Casey K. Ng, Michael Rink, Richard Zigeuner, Christopher G. Wood, Karim Bensalah, Felix K.-H. Chun, Wareef Kabbani, Charles C. Guo, Eiji Kikuchi, Vitaly Margulis, Mesut Remzi, Andrea Haitel, Jay D. Raman, Pierre I. Karakiewicz, Douglas S. Scherr, Jens Hansen, Cord Langner, Weill Medical College of Cornell University [New York], Department of Urology, Medical University Graz, Department of Experimental Pharmacology and Toxicology, Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg] (UKE)-Cardiovascular Research Center, University of Texas Southwestern Medical Center [Dallas]- The University of Texas Health Science Center at Houston (UTHealth), Cancer Prognostics and Health Outcomes Unit, Université de Montréal (UdeM), Keio University School of Medicine [Tokyo, Japan], McGill University = Université McGill [Montréal, Canada], Hospital Weinviertel-Korneuburg-Landesklinikum Korneuburg, Service d'urologie [Rennes] = Urology [Rennes], Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Medizinische Universität Wien = Medical University of Vienna, Cancer Prognostics and Health Outcome Unit, Service d'urologie [Rennes], Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes]
Subjects: Male, MESH: Carcinoma, 030232 urology & nephrology, Disease, urologic and male genital diseases, Nephrectomy, Cancer specific survival, 0302 clinical medicine, MESH: Aged, 80 and over, Urothelial carcinoma, MESH: Treatment Outcome, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, Hazard ratio, MESH: Neoplasm Staging, Middle Aged, Prognosis, Renal pelvicalyceal system, TNM classification, Kidney Neoplasms, 3. Good health, Treatment Outcome, 030220 oncology & carcinogenesis, Cohort, pT3 subclassification, Female, [SDV.IB]Life Sciences [q-bio]/Bioengineering, MESH: Neoplasm Recurrence, Local, Adult, medicine.medical_specialty, Urology, [SDV.CAN]Life Sciences [q-bio]/Cancer, Disease-Free Survival, MESH: Prognosis, 03 medical and health sciences, medicine, Humans, Aged, Neoplasm Staging, Retrospective Studies, MESH: Humans, Genitourinary system, business.industry, Proportional hazards model, Carcinoma, Retrospective cohort study, MESH: Adult, MESH: Retrospective Studies, MESH: Urothelium, MESH: Male, Surgery, MESH: Nephrectomy, MESH: Disease-Free Survival, Upper urinary tract, Neoplasm Recurrence, Local, Urothelium, MESH: Kidney Neoplasms, business, MESH: Female
Abstract: Background The clinical course of pT3 upper tract urothelial carcinoma (UTUC) is highly variable. Objectives The aim of the current study was to validate the clinical and prognostic importance of pT3 subclassification in the renal pelvicalyceal system in a large international cohort of patients. Design, setting, and participants From a multi-institutional international database, 858 renal pelvicalyceal tumors treated with radical nephroureterectomy (RNU) were systematically reevaluated by genitourinary pathologists. Category pT3 pelvic tumors were categorized as pT3a (infiltration of the renal parenchyma on a microscopic level only) versus pT3b (macroscopic infiltration of the renal parenchyma and/or infiltration of peripelvic adipose tissue). Intervention RNU. Measurements Associations of pT3 subclassifications with clinicopathologic features were assessed with the chi-square test. Prognostic impact was assessed with the log-rank test and multivariable Cox regression analyses. Results and limitations Of 858 patients with renal pelvicalyceal tumors, 266 (31%) had pT3 disease. Of these, 146 (54.9%) were classified as pT3a and 120 (45.1%) as pT3b. Compared with pT3a, pT3b cancers were associated with higher tumor grade, nodal disease, and tumor necrosis. Ten-year recurrence-free (pT3a 58% vs pT3b 38%; p 0.001) and cancer-specific (pT3a 60% vs pT3b 39%; p = 0.002) survival rates were lower for patients with pT3b disease. In multivariable analyses, classification pT3b was an independent predictor of both disease recurrence (hazard ratio [HR]: 1.8, p = 0.003) and cancer-specific mortality (HR: 1.7; p = 0.02). The major limitation is the retrospective character of the study. Conclusions Subclassification of pT3 renal pelvicalyceal UTUC helps identify patients who are at increased risk of disease progression and cancer-related death. Further research may help assess the value of subclassification and its inclusion in future editions of the American Joint Committee on Cancer–International Union Against Cancer TNM classification system.
Published: 2012
Full Text: View/download PDF

43. [Muscularis mucosae invasion: prognostic factor for intravesical BCG immunotherapy failure for T1 bladder carcinoma]

Author: Y, Nguyen-Huu, G, Delorme, J, Lillaz, I, Bedgedjian, I, Le Ray-Ferrières, E, Chabannes, S, Bernardini, G, Guichard, H, Bittard, F, Kleinclauss, Service de Néphrologie et Urologie, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques, Laboratoire d'anatomie pathologique [Besancon], Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Jean Minjoz-Université de Franche-Comté ( UFC ), Lipides - Nutrition - Cancer (U866) ( LNC ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC ( HOTE GREFFON ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Etablissement français du sang [Bourgogne-France-Comté] ( EFS [Bourgogne-France-Comté] ) -Université de Franche-Comté ( UFC ), Service d'urologie, andrologie et transplantation rénale, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques, Service d'Anatomie pathologique [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Lipides - Nutrition - Cancer (U866) (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), and Saas, Philippe
Subjects: [SDV.IMM] Life Sciences [q-bio]/Immunology, MESH : Retrospective Studies, MESH : Aged, MESH: Neoplasm Grading, Cystectomy, MESH : Neoplasm Invasiveness, MESH: Prognosis, MESH: Multivariate Analysis, Humans, [ SDV.IMM ] Life Sciences [q-bio]/Immunology, Neoplasm Invasiveness, MESH : BCG Vaccine, MESH : Mucous Membrane, Aged, Retrospective Studies, MESH: Aged, MESH: Carcinoma in Situ, Mucous Membrane, MESH: Humans, MESH : Prognosis, MESH : Neoplasm Recurrence, Local, MESH : Humans, MESH: Cystectomy, MESH: Mucous Membrane, MESH : Multivariate Analysis, MESH: Retrospective Studies, MESH : Follow-Up Studies, MESH: Neoplasm Invasiveness, MESH: Follow-Up Studies, MESH : Disease Progression, Prognosis, MESH : Cystectomy, MESH: Urinary Bladder Neoplasms, MESH: BCG Vaccine, MESH : Carcinoma in Situ, Urinary Bladder Neoplasms, MESH : Urinary Bladder Neoplasms, Multivariate Analysis, BCG Vaccine, Disease Progression, [SDV.IMM]Life Sciences [q-bio]/Immunology, MESH: Disease Progression, Neoplasm Grading, Neoplasm Recurrence, Local, MESH: Neoplasm Recurrence, Local, Carcinoma in Situ, MESH : Neoplasm Grading, Follow-Up Studies
Abstract: International audience; OBJECTIVES: To study the prognostic impact of muscularis mucosae (MM) invasion for pT1 bladder cancer treated by transurethral resection (TUR) and adjuvant Bacille Calmette-Guerin (BCG) intravesical immunotherapy. METHODS: Sixty-six patients treated by BCG intravesical instillations were substaged into pT1a and pT1b, regarding Muscularis Mucosae invasion. Tumor grade, associated carcinoma in situ (CIS), multifocality, tumoral size up to 3cm, BCG maintenance were noted. With a mean follow-up of 50.5±38 months, we studied recurrence, progression, overall and specific survival. Cox's model method was used for multivariate analysis. RESULTS: Tumor recurrence was observed in 30±7% and 43±10% (P=0.29) and tumor progression in 16.3±5% and 39±10% (P=0.04) for pT1a and pT1b. The rate of progression was higher (P=0.04) and progression free survival was decreased (P=0.04) for pT1b. Specific death rates were 11±5% and 21±9% (P=0.28), median overall survival was 80.9 [1.5-92] and 48.2 [12-93] months for pT1a and pT1b. Overall and specific survival weren't different between the two populations (P=0.38; P=0.3). Cystectomy rates were 2.3±2% and 30±9% for pT1a and PT1b (P=0.0006). For pT1a patients, recurrence (P=0.8) or progression rates (P=0.64) were no different regarding BCG maintenance immunotherapy but pT1b population had a better progression free survival with BCG maintenance than without (P=0.0051). Only CIS had prognostic value in multivariate analysis. CONCLUSIONS: Tumors with Muscularis Mucosae invasion have a higher risk of progression and BCG failure. Maintenance immunotherapy should be given to improve results with these patients.
Published: 2012
Full Text: View/download PDF

44. Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era

Author: Ravi Vij, Mahmoud Aljurf, Joseph Pidala, H. Jean Khoury, Richard F. Olsson, Erica D. Warlick, Ian D. Lewis, Matthew D. Seftel, Bipin N. Savani, Brenda W. Cooper, Mitchell S. Cairo, Michael A. Pulsipher, Gorgun Akpek, Tanya L. Pedersen, Andrew S. Artz, Martin S. Tallman, Jean-Yves Cahn, Lars Vindeløv, Abhinav Deol, Celaettin Ustun, Vikas Gupta, Marcos de Lima, Sergio Giralt, Kwang Woo Ahn, Hillard M. Lazarus, Holbrook E Kohrt, Gérard Socié, Yi-Bin Chen, Daniel J. Weisdorf, TheREx, Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF), Division of Haematology, University of Toronto-Princess Margaret Hospital, University of Toronto, Service d'hématologie greffe [Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Subjects: Male, Transplantation Conditioning, Clinical Trials and Observations, medicine.medical_treatment, MESH: Piperazines, Graft vs Host Disease, Hematopoietic stem cell transplantation, Biochemistry, Gastroenterology, Piperazines, Tyrosine-kinase inhibitor, MESH: Unrelated Donors, 0302 clinical medicine, hemic and lymphatic diseases, MESH: Protein Kinase Inhibitors, MESH: Transplantation Conditioning, MESH: Aged, MESH: Middle Aged, Incidence (epidemiology), Hematopoietic Stem Cell Transplantation, Hematology, Middle Aged, Protein-Tyrosine Kinases, 3. Good health, Survival Rate, 030220 oncology & carcinogenesis, Benzamides, Cohort, Imatinib Mesylate, Female, Unrelated Donors, MESH: Neoplasm Recurrence, Local, medicine.drug, Adult, medicine.medical_specialty, MESH: Survival Rate, medicine.drug_class, Immunology, MESH: Graft vs Host Disease, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Protein-Tyrosine Kinases, 03 medical and health sciences, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Internal medicine, medicine, MESH: Transplantation, Homologous, Humans, Transplantation, Homologous, Protein Kinase Inhibitors, Survival rate, MESH: Hematopoietic Stem Cell Transplantation, Aged, MESH: Humans, business.industry, Imatinib, MESH: Adult, Cell Biology, medicine.disease, MESH: Male, Surgery, Pyrimidines, MESH: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, MESH: Pyrimidines, Neoplasm Recurrence, Local, business, MESH: Female, 030215 immunology, Chronic myelogenous leukemia
Abstract: Tyrosine kinase inhibitors (TKIs) and reduced intensity conditioning (RIC)/nonmyeloablative (NMA) conditioning hematopoietic cell transplants (HCTs) have changed the therapeutic strategy for chronic myelogenous leukemia (CML) patients. We analyzed post-HCT outcomes of 306 CML patients reported to the Center for International Blood and Marrow Transplant Research aged 40 years and older undergoing RIC/NMA HCT from 2001 to 2007: 117 (38%) aged 40 to 49 years, 119 (39%) 50 to 59 years, and 70 (23%) 60 years or older. The majority (74%) had treatment with imatinib before HCT. At HCT, most patients aged 40 to 49 years were in chronic phase (CP) 1 (74%), compared with 31% aged 60 years or older. Siblings were donors for 56% aged 40 to 49 years; older cohorts had more unrelated donors. The majority received peripheral blood grafts and RIC across all age groups. 3 year overall survival (54%, 52%, and 41%), day + 100 grade II-IV acute GVHD (26%, 32%, and 32%), chronic GVHD (58%, 51%, and 43%), and 1-year treatment-related mortality (18%, 20%, and 13%) were similar across ages. The 3-year relapse incidence (36%, 43%, and 66%) and disease-free survival (35%, 32%, and 16%) were inferior in the oldest cohort. Importantly, for CP1 patients, relapse and disease-free survival were similar across age cohorts. Allogeneic RIC HCT for older patients with CML can control relapse with acceptable toxicity and survival in TKI-exposed CML, especially if still in CP1.
Published: 2012
Full Text: View/download PDF

45. Prognostic value of fluorine-18 fluorodeoxyglucose positron-emission tomography imaging in patients with head and neck squamous cell carcinoma

Author: Remi Marianovski, G. Potard, Pierre-Yves Le Roux, Pierre-Yves Salaun, Gerald Valette, Solène Querellou, Emmanuel Nowak, Marie-Béatrice Cavarec, Ronan Abgral, Alexandra Le Duc-Pennec, Department of Nuclear Medicine, Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Centre d'Investigation Clinique (CIC - Brest), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Department of ORL
Subjects: Male, Kaplan-Meier Estimate, Multimodal Imaging, 030218 nuclear medicine & medical imaging, Cohort Studies, MESH: Proportional Hazards Models, 0302 clinical medicine, MESH: Fluorodeoxyglucose F18, MESH: Cohort Studies, MESH: Aged, MESH: Statistics, Nonparametric, MESH: Middle Aged, medicine.diagnostic_test, Biopsy, Needle, MESH: Carcinoma, Squamous Cell, MESH: Neoplasm Staging, Middle Aged, Prognosis, Immunohistochemistry, 3. Good health, Head and Neck Neoplasms, Positron emission tomography, 030220 oncology & carcinogenesis, MESH: Survival Analysis, Carcinoma, Squamous Cell, Disease Progression, Female, MESH: Disease Progression, Radiology, MESH: Neoplasm Recurrence, Local, MESH: Radiopharmaceuticals, medicine.drug, medicine.medical_specialty, MESH: Biopsy, Needle, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Positron-Emission Tomography and Computed Tomography, Sensitivity and Specificity, Disease-Free Survival, Statistics, Nonparametric, MESH: Multivariate Analysis, MESH: Prognosis, 03 medical and health sciences, Fluorodeoxyglucose F18, medicine.artery, MESH: Analysis of Variance, medicine, Humans, Neoplasm Invasiveness, In patient, MESH: Kaplan-Meier Estimate, Aged, Neoplasm Staging, Proportional Hazards Models, Retrospective Studies, Fluorodeoxyglucose, Analysis of Variance, Fluorine-18-fluorodeoxyglucose, MESH: Humans, business.industry, Head and neck cancer, Cancer, MESH: Immunohistochemistry, MESH: Retrospective Studies, MESH: Neoplasm Invasiveness, medicine.disease, Survival Analysis, Head and neck squamous-cell carcinoma, MESH: Male, MESH: Sensitivity and Specificity, MESH: Head and Neck Neoplasms, Otorhinolaryngology, Positron-Emission Tomography, Multivariate Analysis, Pulmonary artery, MESH: Disease-Free Survival, Neoplasm Recurrence, Local, Radiopharmaceuticals, Tomography, X-Ray Computed, Nuclear medicine, business, MESH: Female
Abstract: Background High tumor uptake of fluorodeoxyglucose (FDG) is associated with an unfavorable outcome in patients with cancer. We evaluated FDG uptake as a prognostic factor in patients with head and neck squamous cell carcinoma. Methods Maximum standardized uptake values (SUVmax) of tumor, liver, and pulmonary artery were recorded. Ratios of SUVmax from tumor to liver (T/L) and from tumor to pulmonary artery (T/PA) were calculated for each patient. Clinical data, tumor, and SUVmax ratios were compared with disease-free survival (DFS) and overall survival (OS). Results Eighty-nine patients were included: 48 presented a local recurrent disease or distant metastases and 42 died. For both DFS and OS, tumor SUVmax value of 7 was the best cutoff value and 4 and 5 for T/L and T/PA ratios. Multivariate analysis confirmed the independent prognostic value of these 3 thresholds for DFS and OS. Conclusions FDG uptake has a significant and independent relationship with recurrence and survival. © 2011 Wiley Periodicals, Inc. Head Neck, 2012
Published: 2012
Full Text: View/download PDF

46. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma

Author: Wassim Kassouf, Yair Lotan, Christian Bolenz, Giacomo Novara, Theresa M. Koppie, Juan Ignacio Martínez-Salamanca, Kazumasa Matsumoto, Jean Jacques Patard, Armin Pycha, Cord Langner, Jay D. Raman, Vincenzo Ficarra, Harun Fajkovic, Mesut Remzi, Marco Roscigno, Pierre I. Karakiewicz, Douglas S. Scherr, Francesco Montorsi, Eiji Kikuchi, Stefan Tritschler, Vitaly Margulis, Casey K. Ng, Eugene K. Cha, Shahrokh F. Shariat, Behfar Ehdaie, Thomas J. Walton, Alon Z. Weizer, Richard Zigeuner, Karim Bensalah, Thomas F. Chromecki, Hans-Martin Fritsche, Matthias Kormaksson, Christopher G. Wood, Weill Medical College of Cornell University [New York], Departement of Oncological and Surgical Sciences, Universita degli Studi di Padova, Department of Urology, University of Texas Southwestern Medical Center [Dallas]- The University of Texas Health Science Center at Houston (UTHealth), Medical University Graz, Hospital Weinviertel-Korneuburg-Landesklinikum Korneuburg, Service d'urologie [Rennes] = Urology [Rennes], Hôpital Pontchaillou-CHU Pontchaillou [Rennes], University of Michigan [Ann Arbor], University of Michigan System, Mannheim Medical Center, Universität Heidelberg [Heidelberg], General Hospital of Bolzano, Health Robotics S.r.l., Service d'urologie, Hôpital Bicêtre-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11), Department of urology, Università Vita-Salute San Raffaele, Cancer Prognostics and Health Outcome Unit, Université de Montréal (UdeM), Service d'urologie [Rennes], CHU Pontchaillou [Rennes]-Hôpital Pontchaillou-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Cha Eugene, K., Shariat Shahrokh, F., Kormaksson, Matthia, Novara, Giacomo, Chromecki Thomas, F., Scherr Douglas, S., Lotan, Yair, Raman Jay, D., Kassouf, Wassim, Zigeuner, Richard, Remzi, Mesut, Bensalah, Karim, Weizer, Alon, Kikuchi, Eiji, Bolenz, Christian, Roscigno, Marco, Koppie Theresa, M., Ng Casey, K., Fritsche Hans, Martin, Matsumoto, Kazumasa, Walton Thomas, J., Ehdaie, Behfar, Tritschler, Stefan, Fajkovic, Harun, Martinez Salamanca Juan, I., Pycha, Armin, Langner, Cord, Ficarra, Vincenzo, Patard Jean, Jacque, Montorsi, Francesco, Wood Christopher, G., Karakiewicz Pierre, I., and Margulis, Vitaly
Subjects: Oncology, Male, MESH: Carcinoma, Time Factors, Lymphovascular invasion, medicine.medical_treatment, MESH: Lymphatic Metastasis, 030232 urology & nephrology, Kaplan-Meier Estimate, MESH: Risk Assessment, Nephrectomy, Nephroureterectomy, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, Nomogram, MESH: Proportional Hazards Models, 0302 clinical medicine, Risk Factors, MESH: Risk Factors, Medicine, MESH: Ureteral Neoplasms, Stage (cooking), urothelial carcinoma, Survival prediction, Upper urinary tract, MESH: Treatment Outcome, MESH: Urologic Surgical Procedures, MESH: Aged, MESH: Middle Aged, MESH: Urologic Neoplasms, Middle Aged, 3. Good health, Europe, Treatment Outcome, MESH: Ureter, 030220 oncology & carcinogenesis, Lymphatic Metastasis, Urologic Surgical Procedures, Female, Urothelial carcinoma, [SDV.IB]Life Sciences [q-bio]/Bioengineering, MESH: Neoplasm Recurrence, Local, medicine.medical_specialty, Urologic Neoplasms, Urology, Risk Assessment, Disease-Free Survival, MESH: Multivariate Analysis, 03 medical and health sciences, Internal medicine, Adjuvant therapy, Humans, MESH: Kaplan-Meier Estimate, Aged, Proportional Hazards Models, Retrospective Studies, MESH: Humans, business.industry, Proportional hazards model, Ureteral Neoplasms, Carcinoma in situ, Carcinoma, MESH: Time Factors, Retrospective cohort study, MESH: Retrospective Studies, medicine.disease, MESH: Urothelium, MESH: Male, MESH: North America, MESH: Nephrectomy, Multivariate Analysis, North America, MESH: Disease-Free Survival, MESH: Europe, Neoplasm Recurrence, Local, Ureter, Urothelium, business, MESH: Female
Abstract: Background: Novel prognostic factors for patients after radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC) have recently been described. Objective: We tested the prognostic value of pathologic characteristics and developed models to predict the individual probabilities of recurrence-free survival (RFS) and cancer-specific survival (CSS) after RNU. Design, setting, and participants: Our study included 2244 patients treated with RNU without neoadjuvant or adjuvant therapy at 23 international institutions. Tumor characteristics included T classification, grade, lymph node status, lymphovascular invasion, tumor architecture, location, and concomitant carcinoma in situ (CIS). The cohort was randomly split for development (12 centers, n = 1273) and external validation (11 centers, n = 971). Interventions: All patients underwent RNU. Measurements: Univariable and multivariable models addressed RFS, CSS, and comparison of discrimination and calibration with American Joint Committee on Cancer (AJCC) stage grouping. Results and limitations: At a median follow-up of 45 mo, 501 patients (22.3%) experienced disease recurrence and 418 patients (18.6%) died of UTUC. On multivariable analysis, T classification (p for trend
Published: 2012
Full Text: View/download PDF

47. Markers of recurrence and long-term morbidity in craniopharyngioma: a systematic analysis of 171 patients

Author: Fabrice Bonnet, A. Gautier, Ariane Godbout, Mathieu Coudert, Gilles Brassier, Catherine Grosheny, Laurent Riffaud, Philippe Touraine, Christian Sainte-Rose, Marc de Kerdanet, Carine Courtillot, Christel Jublanc, Elisabeth Thibaud, Isabelle Tejedor, Jean-Yves Poirier, Remy Van Effenterre, Foie, métabolismes et cancer, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Service d'endocrinologie diabétologie et nutrition [Rennes], Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-CHU Pontchaillou [Rennes]-Hôpital Anne-de-Bretagne, Endocrinology Division, Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal (UdeM)-Université de Montréal (UdeM)-Department of Medicine, CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Pierre et Marie Curie - Paris 6 (UPMC), Modeling in Clinical Research, Université Pierre et Marie Curie - Paris 6 (UPMC)-EA 3974, Service de Pédiatrie, Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Service de neurochirurgie [Rennes] = Neurosurgery [Rennes], CHU Pontchaillou [Rennes], Service de neurochirurgie pédiatrique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Craniopharyngioma Study Group, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université de Rennes (UR)-CHU Pontchaillou [Rennes]-Hôpital Anne-de-Bretagne, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -CHU Pontchaillou [Rennes]-Hôpital Anne-de-Bretagne, Centre de recherche du Centre Hospitalier de l'Université de Montréal ( CRCHUM ) -Department of Medicine, Department of Endocrinology and Reproductive Medicine, CHU Pitié-Salpêtrière [APHP]-Centre de Référence des Maladies Endocriniennes rares de la croissance et des maladies gynécologiques rares, Université Pierre et Marie Curie - Paris 6 ( UPMC ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -EA 3974, Department of Biostatistics and Medical Informatics, CHU Pitié-Salpêtrière [APHP], Department of Endocrinology and Metabolism, Service de neurochirurgie [Rennes], Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Department of Neurosurgery, and Le Corre, Morgane
Subjects: Male, Pediatrics, MESH : Retrospective Studies, Endocrinology, Diabetes and Metabolism, Clinical Biochemistry, MESH : Child, Preschool, Biochemistry, MESH: Craniopharyngioma, Cohort Studies, Craniopharyngioma, 0302 clinical medicine, Endocrinology, MESH : Child, Quality of life, MESH: Child, MESH : Female, MESH : Craniotomy, [ SDV.IB ] Life Sciences [q-bio]/Bioengineering, Age of Onset, Child, MESH: Cohort Studies, [SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, MESH : Prognosis, MESH: Middle Aged, MESH : Neoplasm Recurrence, Local, MESH: Follow-Up Studies, MESH : Adult, [ SDV.MHEP.EM ] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, Middle Aged, [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, Prognosis, MESH : Age of Onset, 3. Good health, 030220 oncology & carcinogenesis, Child, Preschool, MESH: Survival Analysis, MESH : Social Adjustment, Female, [SDV.IB]Life Sciences [q-bio]/Bioengineering, France, Social Adjustment, MESH: Neoplasm Recurrence, Local, Craniotomy, Cohort study, MESH: Intracranial Hypertension, Adult, medicine.medical_specialty, Adolescent, MESH : Male, MESH: Age of Onset, MESH: Craniotomy, MESH : Cohort Studies, Context (language use), MESH: Prognosis, 03 medical and health sciences, MESH : Intracranial Hypertension, MESH : Adolescent, Internal medicine, MESH : Craniopharyngioma, medicine, Humans, MESH : Middle Aged, MESH : France, Survival rate, Survival analysis, Retrospective Studies, [SDV.IB] Life Sciences [q-bio]/Bioengineering, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, Biochemistry (medical), MESH: Child, Preschool, MESH: Quality of Life, MESH : Follow-Up Studies, Retrospective cohort study, MESH: Adult, MESH: Retrospective Studies, MESH : Quality of Life, medicine.disease, Survival Analysis, MESH: Social Adjustment, MESH: Male, Surgery, MESH: France, Quality of Life, MESH : Survival Analysis, Age of onset, Intracranial Hypertension, Neoplasm Recurrence, Local, business, MESH: Female, 030217 neurology & neurosurgery, Follow-Up Studies
Abstract: International audience; CONTEXT: Craniopharyngiomas are often associated with an unfavorable prognosis, but data on their long-term consequences are sparse. OBJECTIVE: The aim of the study was to identify markers of recurrence and factors associated with compromised social rehabilitation and altered quality of life in a large cohort of patients with either childhood-onset (CO) or adult-onset craniopharyngioma. METHODS: Retrospective analysis was performed for 171 patients treated for craniopharyngioma in two academic centers in France between 1972 and 2009. For each subject, data were collected concerning clinical presentation, imaging features, visual sequelae, endocrine and metabolic impact, treatment modalities (surgery, radiotherapy), recurrence-free survival rate, and social insertion, as well as answers to the WHO-QOL BREF questionnaire. RESULTS: A total of 65 CO and 106 adult-onset patients were reviewed. If CO was diagnosed before the age of 10 yr, this was associated with a higher incidence of obesity, blindness, and panhypopituitarism, and only 40.7% of subjects had adequate work or school attendance compared to 72.4% of patients with later disease onset. Initial symptoms of intracranial hypertension (SIHT), pterional surgery, and multiple surgery were associated with obesity and poorer social insertion. No determinant of quality of life was identified. In the subgroup of patients treated in the 1990s and later, the progression rate was 59.4% in patients with residual tumor on magnetic resonance imaging compared with a 19.8% recurrence rate in the group with apparently complete resection. Recurrence/progression correlates significantly with male gender, early onset (before 10 yr), and SIHT, but only SIHT at presentation remained a significant predictor with multivariate analysis. CONCLUSIONS: Craniopharyngioma continues to be associated with severe outcomes. Higher morbidity rates are found in patients with early-onset disease (before 10 yr), initial SIHT, or in whom pterional surgery was required. Markers of recurrence are difficult to identify, with SIHT being the most powerful predictor.
Published: 2012
Full Text: View/download PDF

48. Analyse rétrospective de 24 glioblastomes récidivant après radiochimiothérapie concomitante et traités par nitrosourées ou par l'association irinotécan et bévacizumab. [Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab]

Author: Vauleon, Elodie, Mesbah, Habiba, Gedouin, Daniel, Lecouillard, Isabelle, Louvel, Guillaume, Hamlat, Abderrahmane, Riffaud, Laurent, Carsin, Béatrice, Quillien, Véronique, Audrain, Odile, Lesimple, Thierry, Institut de Génétique et Développement de Rennes (IGDR), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS), Département d'oncologie médicale [Rennes], CRLCC Eugène Marquis (CRLCC), Département d'informatique médicale, Service de radiothérapie, Service de neurochirurgie [Rennes] = Neurosurgery [Rennes], CHU Pontchaillou [Rennes], Service de radiologie et imagerie médicale [Rennes] = Radiology [Rennes], Service de Biologie, De Villemeur, Hervé, Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Centre National de la Recherche Scientifique (CNRS)
Subjects: MESH: Radiation-Sensitizing Agents, recurrence, MESH: Carmustine, [SDV.CAN]Life Sciences [q-bio]/Cancer, bevacizumab, MESH: Lomustine, MESH: Dacarbazine, [SDV.CAN] Life Sciences [q-bio]/Cancer, MESH: Nitrosourea Compounds, neoplasms, MESH: Cohort Studies, irinotecan, MESH: Angiogenesis Inhibitors, MESH: Chemoradiotherapy, MESH: Aged, MESH: Humans, MESH: Middle Aged, MESH: Glioblastoma, glioblastoma, MESH: Adult, MESH: Retrospective Studies, eye diseases, MESH: Drug Therapy, Combination, MESH: Antineoplastic Combined Chemotherapy Protocols, MESH: Antibodies, Monoclonal, Humanized, MESH: Chemotherapy, Adjuvant, MESH: Brain Neoplasms, MESH: Camptothecin, sense organs, MESH: Neoplasm Recurrence, Local
Abstract: International audience; Despite progress in the initial management of glioblastoma (GB), the vast majority of patients will experience recurrence within 2-3 years. The medical treatment of these recurrences is being modified by the use of antiangiogenic therapies. Twenty-four patients, who relapsed from GB after chemoradiation followed by adjuvant temozolomide in Rennes, were treated by conventional chemotherapy (nitrosourea) or by the combination of irinotecan and bevacizumab. In this retrospective analysis, overall survival from diagnosis of recurrence was significantly longer in patients treated with the combination of bevacizumab and irinotecan than with nitrosourea (5 months versus 11.5 months). The combination of irinotecan and bevacizumab appeared to provide clinical benefit to patients with recurrent GB.
Published: 2012
Full Text: View/download PDF

49. The risk of upstaged disease increases with body mass index in low-risk prostate cancer patients eligible for active surveillance

Author: Alexandre de la Taille, Xavier Durand, Francis Vacherot, Claude-Clément Abbou, Younes Bayoud, Evanguelos Xylinas, Stéphane Terry, Guillaume Ploussard, Yves Allory, Laurent Salomon, INSERM U955, équipe 7, Service d'urologie [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Dynamique de l'information génétique : bases fondamentales et cancer (DIG CANCER), Centre National de la Recherche Scientifique (CNRS)-Institut Curie [Paris]-Université Pierre et Marie Curie - Paris 6 (UPMC), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Département de pathologie [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut Curie [Paris]-Centre National de la Recherche Scientifique (CNRS), and Guellaen, Georges
Subjects: Male, obesity, medicine.medical_treatment, 030232 urology & nephrology, MESH: Neoplasm Grading, Overweight, urologic and male genital diseases, 030218 nuclear medicine & medical imaging, Cohort Studies, Prostate cancer, 0302 clinical medicine, MESH: Obesity, MESH: Cohort Studies, 2. Zero hunger, MESH: Aged, MESH: Risk, MESH: Middle Aged, Prostatectomy, low risk, Middle Aged, prostate cancer, MESH: Predictive Value of Tests, 3. Good health, MESH: Prostate-Specific Antigen, medicine.symptom, MESH: Neoplasm Recurrence, Local, Risk, Biochemical recurrence, medicine.medical_specialty, Urology, body mass index, Disease-Free Survival, MESH: Body Mass Index, 03 medical and health sciences, MESH: Prostatectomy, Predictive Value of Tests, Internal medicine, medicine, [SDV.BBM] Life Sciences [q-bio]/Biochemistry, Molecular Biology, Humans, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, Survival analysis, Aged, Retrospective Studies, Gynecology, MESH: Humans, business.industry, active surveillance, Prostatic Neoplasms, MESH: Retrospective Studies, Odds ratio, Prostate-Specific Antigen, medicine.disease, radical prostatectomy, MESH: Male, MESH: Prostatic Neoplasms, MESH: Disease-Free Survival, Neoplasm Grading, Neoplasm Recurrence, Local, business, Body mass index, Primary Gleason Pattern
Abstract: International audience; BACKGROUND: Obese patients have a greater risk of adverse pathologic features and biochemical recurrence after radical prostatectomy (RP). The impact of body mass index (BMI) on the risk of reclassification and deferred treatment in active surveillance (AS) programs has not been thoroughly assessed. OBJECTIVE: To evaluate the impact of BMI on the risk of reclassification for AS eligibility. DESIGN, SETTING, AND PARTICIPANTS: We assessed 230 men who underwent an immediate RP and were eligible for AS according to the following criteria: prostate-specific antigen (PSA) ≤ 10 ng/ml, clinical stage T1c, Gleason score ≤ 6, fewer than three positive cores, extent of cancer in any core 10 yr. INTERVENTION: All patients underwent a standardised 21-core biopsy and RP at our department between January 2001 and December 2010. MEASUREMENTS: Reclassification was defined as upstaged disease (pathologic stage >pT2) and/or upgraded disease (Gleason score ≥ 7; primary Gleason pattern 4) in RP specimens. PSA outcomes were also recorded. RESULTS AND LIMITATIONS: Mean BMI was 26.4 kg/m(2), and 13% of patients were obese (BMI >30). Mean BMI was the only preoperative factor significantly associated with the risk of upstaged disease. In multivariate analysis, BMI >30 remained an independent predictive factor for upstaged disease (p=0.003; odds ratio: 4.2). The risk of upgraded disease (primary Gleason pattern 4) was significantly decreased 4.5-fold in large prostate glands (>50 ml; p=0.008). The biochemical recurrence-free survival curves were not significantly different between men who were or were not overweight (p=0.950). CONCLUSIONS: Obese men are at higher risk of upstaged disease, with a proportion of 30% of pT3 disease in RP specimens. BMI should be taken into account for inclusion of low-risk prostate cancer patients in AS programs, and our results may help urologists better inform their obese patients eligible for AS about this risk of reclassification and improve treatment decision making.
Published: 2012
Full Text: View/download PDF

50. Plasmodium falciparum STEVOR proteins impact erythrocyte mechanical properties

Author: Odile Mercereau-Puijalon, Catherine Lavazec, Sylvie Perrot, Emmanuel Bischoff, Kirk W. Deitsch, Pierre Buffet, Thomas J. Templeton, Stéphane Egée, Guillaume Bouyer, Innocent Safeukui, Peter H. David, Sohini Sanyal, Department of Microbiology and Immunology, Cornell University [New York], Mer et santé (MS), Station biologique de Roscoff [Roscoff] (SBR), Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC), Immunologie moléculaire des parasites, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Génétique et Génomique des Insectes vecteurs, Immunité et Infection, Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR113-Université Pierre et Marie Curie - Paris 6 (UPMC), Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR113-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), and Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Erythrocytes, MESH: Carcinoma, Papillary, MESH: Adenocarcinoma, Follicular, MESH: Erythrocyte Membrane, Biochemistry, MESH: Aged, 80 and over, Parasite hosting, Malaria, Falciparum, Fluorescent Antibody Technique, Indirect, Cells, Cultured, MESH: Plasmodium falciparum, MESH: Treatment Outcome, MESH: Aged, 0303 health sciences, MESH: Middle Aged, biology, MESH: Real-Time Polymerase Chain Reaction, MESH: Erythrocytes, MESH: Malaria, Falciparum, Hematology, MESH: Follow-Up Studies, MESH: Iodine Radioisotopes, 3. Good health, Cell biology, Erythrocyte membrane, Real-time polymerase chain reaction, MESH: Thyroid Neoplasms, MESH: Neoplasm Recurrence, Local, MESH: Cells, Cultured, MESH: Survival Rate, Transgene, Immunology, Plasmodium falciparum, Antigens, Protozoan, Real-Time Polymerase Chain Reaction, 03 medical and health sciences, Red Cells, Iron, and Erythropoiesis, Deep tissue, Humans, MESH: Fluorescent Antibody Technique, Indirect, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, RNA, Messenger, Gene, 030304 developmental biology, MESH: RNA, Messenger, MESH: Humans, 030306 microbiology, Erythrocyte Membrane, MESH: Adult, Cell Biology, biology.organism_classification, MESH: Male, MESH: Disease-Free Survival, MESH: Female, Function (biology), MESH: Antigens, Protozoan
Abstract: International audience; Infection of erythrocytes with the human malaria parasite, Plasmodium falciparum, results in dramatic changes to the host cell structure and morphology. The predicted functional localization of the STEVOR proteins at the erythrocyte surface suggests that they may be involved in parasite-induced modifications of the erythrocyte membrane during parasite development. To address the biologic function of STEVOR proteins, we subjected a panel of stevor transgenic parasites and wild-type clonal lines exhibiting different expression levels for stevor genes to functional assays exploring parasite-induced modifications of the erythrocyte membrane. Using this approach, we show that stevor expression impacts deformability of the erythrocyte membrane. This process may facilitate parasite sequestration in deep tissue vasculature.
Published: 2012
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Journal

Database

Publisher

114 results on '"MESH: Neoplasm Recurrence, Local"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources